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Overview of thesis 
Rheumatoid arthritis (RA) is one of the most common chronic systemic autoimmune 
inflammatory diseases, which is associated with an increased mortality rate, attributed to 
premature cardiovascular disease (CVD). Key drivers of mortality from CVD in RA are 
fuelled by multiple factors.  
Rheumatoid arthritis disease profiling, particularly seropositivity, presence of extra-articular 
disease and high disease activity, confer an increased mortality risk. Traditional CVD risk 
factors (hypertension, diabetes mellitus, dyslipidaemia, obesity) are influenced by both 
inflammation inherent to RA, and pharmacodynamics of anti-rheumatic drugs. 
Notwithstanding the above, the current paradigm shift recognises RA as an independent risk 
factor for CVD.  
Similar to the rest of Africa, local data on the prevalence of CVD in RA are limited. With an 
increase in non-communicable diseases and longevity, the RA burden in South Africa (SA) is 
expected to increase. Local studies are needed to stratify practice in cardio-protective 
strategies and improved long term outcomes in RA. This study aims to determine the 
prevalence of CVD in RA, describe the prevalence of CVD risk factors in RA and describe 
the relationship between RA disease activity and CVD.  
A retrospective, chart review of all patients with RA according to the American College of 
Rheumatology 1987/2010 Classification criteria, attending the arthritis clinic in King Edward 
VIII hospital, a tertiary public healthcare academic teaching hospital in KwaZulu-Natal, SA, 
during the period August 2017 to March 2018, was undertaken. Patients younger than 18 
years of age, or with RA and any other concomitant connective tissue disease or overlap 
syndrome were excluded. The study group included 150 patients with RA.  
The demographic details, duration of the RA disease, traditional CVD risk factors, simplified 
disease activity index (SDAI) and health assessment questionnaire (HAQ) were documented. 
In addition, results of electrocardiogram, echocardiogram, haemoglobin, glycated 
haemoglobin, lipid studies and estimated glomerular filtration rate were recorded. 
Cardiovascular disease was found in 16% of the total study cohort, with an age, gender and 
ethnic differential. Coronary artery disease was the most common CVD finding in RA 
patients. The burden of traditional CVD risk factors in RA is high, with hypertension, 
diabetes mellitus, dyslipidaemia, physical inactivity and chronic kidney disease of particular 
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concern. No significant correlation was observed between RA disease activity, seropositivity 
and CVD in RA however, extra-articular disease was more common among patients with 
CVD. Echocardiographic evidence of subclinical cardiac disease in RA is common. 
Significant disparity was observed between various CVD risk assessment models at different 
levels of risk, which cautions a comprehensive CVD risk assessment model that stratifies 
discriminately is needed in patients with RA. The study provides knowledge of CVD burden 
and risk in RA patients locally, and serves as a foundation for further research in preventative 
strategies that offer significant survival benefits.  
The main limitation in this study is that the study cohort consisted mainly of Black and Indian 
patients and therefore the findings may not be generalised across all ethnic groups. 
Furthermore as this was a relatively small study conducted in a single public hospital, which 
is urban based, conclusions from this study may not be applicable to a rural setting or to all 
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Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease, 
characterized by a symmetrical, peripheral polyarthritis [1]. The peak age of onset is between 
30 and 50 years, and the disease has a predilection for women compared to men (3:1) [2]. It is 
one of the most common inflammatory arthritis, with a natural history resulting in joint 
destruction, functional impairment and increased mortality [2]. In addition to the articular 
disease, extra-articular manifestations are seen in approximately 50% of all patients with RA 
at some point during the course of disease [1].  
  
The mortality rate amongst RA patients is increased by 70% compared to the general 
population [3], and the leading cause of death in RA is cardiovascular disease (CVD) [3, 4]. 
Both traditional and non-traditional factors combine to increase the adverse CVD risk profile 
in patients with RA, with CVD deaths occurring five to ten years prematurely compared to 




The exact immuno-pathogenesis of RA remains unknown [5], but it is postulated to involve 
genetic and environmental factors, with a complex interaction between T-cells, B-cells and 
pro-inflammatory cytokines. Cytokines act as messengers that activate effector cells causing 
the local and systemic symptoms associated with this disease [6]. 
 
The earliest detectable pre-clinical stage is the breakdown of self-tolerance. In the rheumatoid 
joint, activation of T-cells stimulate macrophages and synoviocytes to generate pro-
inflammatory mediators which eventually destroy cartilage and bone [6]. T-cells help B-cells 
produce antibodies that promote joint inflammation. 
Activated B-cells form plasma cells, which produce rheumatoid factor (RF) and anti-cyclic 
citrullinated peptide (CCP) antibodies [7]. Rheumatoid factor contributes to the pathogenic 
process by forming large immune complexes inside the joint, fixing complement and 
promoting chemoattractant [7]. In contrast, anti-CCP antibodies are directed against 
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deiminated peptides and they recognise citrulline containing matrix proteins, which enhance 
the expression of self-reactivity [7]. 
The pro-inflammatory cytokine; tumour necrosis factor-alpha (TNF-α), plays a critical role in 
the pathogenesis of RA [8]. Tumour necrosis factor-alpha together with interleukin (IL) 1, 6 
and 17, increases the expression of receptor activator of nuclear factor kappa ligand 
(RANKL) which stimulates osteoclast differentiation and bone resorption in the joint, thus 
promoting osteoclastogenesis. Simultaneously, TNF-α also inhibits osteoblast differentiation, 
thereby actively suppressing new bone formation. Furthermore IL 6, IL 1 and TNF-α 
together, promote the synthesis of C-reactive protein (CRP) in hepatocytes. In addition to 
eliminating infection, CRP plays a regulatory role in inflammation and atherosclerotic 
thrombosis [3, 9]. Since CRP is a direct measure of synovial inflammation, and a by-product 
of inflammatory reactions in RA, it is therefore a useful marker of disease activity [3, 9]. 
Emerging evidence supports the role of CRP as a pro-inflammatory bone destructive 
molecule in the pathogenesis of RA [9].   
 
Persistently elevated CRP levels exacerbate tissue damage, promote lipid metabolism 
dysregulation and increase the risk of cardiovascular complications [6]. The combined effects 
of TNF-α, IL-6, acute phase reactants, immune complexes, and pro inflammatory high 
density lipoprotein (HDL) phenotype, increase endothelial activation and render 
atheromatous plaques unstable [3, 10]. Cytokine driven insulin resistance of muscle and 
adipose tissue results in an “inflammatory metabolic” syndrome [10]. 
Risk factors for rheumatoid arthritis 
 
Several factors influence the development, rate of progression and severity of RA (Figure 1). 
Although several genetic loci have been described, the epitope of the human leucocyte 
antigen (HLA)-DRB1*04 cluster has been identified in greater than 80% of patients with RA 
[11]. Patients expressing the HLA-DRB1*04 cluster inherit a higher risk for nodular disease, 
major organ involvement and surgery related to joint destruction [6]. Further, strengthening 
the genetic theory are twin studies that show a concordance rates of 15 to 30% among 
monozygotic twins and 5% among dizygotic twins [10]. 
  
Gene-environment interactions underlie the association of different genotypes in the various 
geographical and cultural settings [4]. Locally, an urban-rural regional variation of disease, 
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with a higher prevalence in the South African urban population compared to virtually no 
cases reported in some rural areas is observed [12-16]. Furthermore, studies also suggest a 
role for occupational factors, such as exposure to dust, asphalt and silica, resulting in 
bronchial stress and thereby increasing the risk for anti-CCP antibody positive RA [10]. 
  
Seropositive and extra-articular RA is strongly associated with cigarette smoking [4]. Both 
smoking intensity and duration increases the risk of development of disease. Additionally, 
citrullination of proteins in broncho-alveolar fluid occurs more often in smokers. The long-
term tobacco smoke exposure and citrullination of proteins induce self-reactivity resulting in 
anti-CCP positive disease, which confers a less favourable prognosis than anti-CCP negative 
disease [10].   
  
Although there is no clear role for a hormonal influence, it is felt that oestrogen stimulates 
TNF-α resulting in an increased risk in women, with women usually having a poorer outcome 
than men [4, 10]. Similarly there is conflicting data on lifestyle and education level, and 
disease occurrence. Whilst, several studies found a higher prevalence in highly educated, 
high-income classes, compared with uneducated, lower-income classes, other studies have 
not confirmed these findings [4]. 
  
Infectious agents are increasingly being implicated in the aetiology of RA, on a postulated 
background of molecular mimicry. The formation of immune complexes during an infection 
triggers the induction of RF. Possible infectious triggers include Epstein-Barr virus, 
cytomegalovirus, parvovirus, Proteus species, Escherichia coli and mycoplasma [4, 10]. 
Additional studies involving clinical bacterial signatures associated with anti-CCP antibody 




Figure 1. Postulated factors associated with the development of rheumatoid arthritis [10] 
 
Epidemiology 
Rheumatoid arthritis is not a recent disease and descriptions of symmetric, chronic 
polyarthritis with characteristic deformities date back to Rome in 100 BC and India in 500 
BC [17]. 
  
The epidemiology of RA is well described in developed countries, with estimates from 
Western Europe and North America reporting a global prevalence of between 0.3% and 1% 
[18]. In contrast, RA is thought to have a lower prevalence, with a milder disease course in 
developing countries [12]. 
 
The Global Burden of Disease 2010 study, conducted in 187 countries, based on the 1987 
American College of Rheumatology (ACR) classification criteria for RA, found a global 
prevalence of RA of 0.24%, however the true global prevalence of RA remains unknown 
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[18]. The study used the outdated 1987 ACR classification criteria for RA, which fails to 
recognize early RA, and hence the use of this classification criteria excluded such patients. 
Further, since prevalence data was not available for multiple regions, Sub-Saharan Africa 
included, data was then modelled using a meta-regression tool [18]. This could significantly 
underestimate the actual burden of disease in African countries, and therefore the true global 
prevalence of RA.  
 
There is a paucity of prevalence data for RA from Africa and a recent systematic review 
found an overall prevalence which ranged from 0.13% in Algeria to 2.54% in South Africa 
(SA) [19]. Differences in urbanisation, cultural and geographical diversity amongst countries 
contribute to the significant statistical heterogeneity in the overall meta-analysis [12].   
 
Similar to the rest of Africa, local data for prevalence of RA in SA are limited, with 
environmental factors and the urban-rural gradient contributing to the differences seen in 
various South African populations [13]. The highest prevalence of 0.9% was found in a 
mixed urban community in Soweto, followed by the Xhosa of Transkei (0.68%), the Sotho’s 
of Lesotho (0.3%), and the Tswana of Western Transvaal with 0.1% [13], with the lowest 
(0%) prevalence in rural Venda, a historic district of Northern SA occupied by Venda people, 
now part of the Limpopo province [12].  
 
In spite of the low prevalence, RA contributes significantly to morbidity and quality of life 
and a local study found that poor functioning was predictive of substantial functional 
disability and suboptimal mental health in South African patients with early RA even after 12 
months of joint targeted therapy [20]. 
  
Clinical expression of disease 
 
The articular expression of disease includes mono-, oligo- or poly-articular symmetrical 
synovitis, with early morning stiffness lasting more than one hour [7]. Both small and large 
joints are affected, with untreated or inadequately treated disease progressing to joint 




Extra-articular disease occurs in almost 50% of patients with RA, at some point during the 
course of disease [1]. Risk factors for extra-articular disease include smokers, early onset 
disability and RF or anti-CCP antibody positive disease. The most frequent extra-articular 
manifestations include subcutaneous nodules, secondary Sjogren’s syndrome, pulmonary 
nodules and a normochromic, normocytic anaemia [7, 22]. Other manifestations include 
osteoporosis, scleritis, episcleritis, vasculitis, pulmonary disease (pleural effusions, interstitial 
lung disease, idiopathic pulmonary fibrosis, pulmonary nodules, pulmonary hypertension), 
haematological disease (thrombocytopaenia, leucopaenia), neurological disease 
(mononeuritis multiplex, peripheral neuropathy, nerve entrapment), and cardiovascular 
disease (cardiomyopathy, pericarditis, valvular heart disease, coronary artery disease (CAD) 
and atherosclerosis) [7]. Extra-articular disease is associated with an increased mortality due 
to CVD [22-24].  
 
Diagnostic criteria for rheumatoid arthritis  
 
Prior to 2010, the 1987 ACR classification criteria for RA (Table 1) were used [25, 26]. The 
criteria included symmetrical small joint involvement, early morning stiffness, radiological 
disease and a minimum period of six weeks duration of symptoms before a diagnosis could 




















Abbreviations: MCP, metacarpophalangeal; PIP proximal interphalangeal 
 
The above criteria were criticised for lack of sensitivity for early disease, which lead to the 
2010 ACR/ European League Against Rheumatism (ACR/EULAR) RA Classification 
Criteria (Table 2), which is currently used [25, 27]. The revised criteria is more 
comprehensive, with the inclusion of inflammatory markers and anti-CCP seropositivity, 










Table 2. The 2010 American College of Rheumatology/European League Against 
Rheumatism  classification criteria for rheumatoid arthritis [27]  
 
 
Large joints refer to shoulders, elbows, hips, knees and ankles 
Small joints refer to metacarpophalangeal joints, proximal 
interphalangeal joints, second through to fifth metatarsophalangeal 
joints, thumb interphalangeal joints and wrists 
Low positive values refer to values less than three times the upper limit of 
normal 
High positive values refer to values greater than three times the upper 
limit of normal 










Disease activity  
 
Disease severity is a predictor of mortality [4], with premature mortality from CVD related to 
the number of inflamed joints [28], and persistently elevated inflammatory markers [3].  
There are several disease activity scores available [2, 29]. A composite disease activity score 
is obtained by using a combination of clinical examination of tender and swollen joints, 
global assessments and laboratory investigations [29]. The ACR core set for disease activity 
includes the following [2]: 
  
 Tender joint count 
 Swollen joint count 
 Patient pain assessment 
 Patient global assessment 
 Doctor global assessment 
 Function  
 Acute phase reactant 
 Radiographic analysis 
 
The twenty eight joint count is most widely used. Function and pain is assessed in a patient-
centred health assessment questionnaire (HAQ). The HAQ provides fundamental knowledge 
about a patient’s health, functional status and quality of life from their own personal 
perspective [30]. The HAQ has been validated in multiple studies, such as prediction of 
successful aging, inversion of the therapeutic pyramid in RA, and examination of mortality 
risks in RA, work capacity and performance, occupation and the ability to live independently 
[30].  
 
Composite scores provide a more accurate reflection of overall state of disease compared to 
individual measurements. The most widely used composite scores is the Disease Activity 
Score (DAS) 28, involving tender and swollen 28 joint count together with acute phase 
reactants and patient global assessment (Table 3) [2]. The Simplified Disease Activity Index 
(SDAI) combines the sum of tender and swollen 28 joint count, patient and doctor global 
assessment and acute phase reactants, whilst the Clinical Disease Activity Index (CDAI) is a 
modification of the SDAI, without the inclusion of acute phase reactants (Table 3) [2]. Acute 
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phase reactants measured include the CRP or erythrocyte sedimentation rate (ESR). These 
composite indices are in excellent agreement, correlate with function and radiographic 
changes, and have been validated in multiple studies [31-34]. It allows for consistency of 
patient evaluation by multiple physicians, improves patient’s understanding of their disease 
activity by provision of a single number, and facilitates modification of therapeutic decisions, 
with consequent improved patient outcomes [31, 33].  
  
The score further defines disease activity into remission, low, moderate or high disease 
activity (Table 3), which identifies poorly controlled patients, and allows for targeted 
treatment goals to be achieved [29, 35]. 
 




Management of rheumatoid arthritis  
 
The benefits of initiating early, goal directed therapy, where the target is disease remission, 
has downstream effects of joint preservation and reduced disability [21, 29]. The challenges 
of rheumatologists managing RA in the developing world are different to those of the 
developed world. South African Rheumatism and Arthritis Association (SARAA) have 
developed an algorithmic guideline for management of RA in SA [21]. Disease modifying 
anti rheumatic drugs (DMARD) play a pivotal immune-modulatory role in RA. 
 
Methotrexate is the first line anchor synthetic DMARD used universally [36]. It inhibits 
dihydrofolate reductase, an enzyme needed for deoxyribonucleic acid (DNA) synthesis, with 
resultant downregulation of inflammatory pathways [1]. It has excellent efficacy and 
tolerability, with a convenient weekly dosing regimen [12]. Leflunomide is an 
immunomodulatory drug, useful in patients who are unresponsive to, or intolerant of, 
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methotrexate.  However, drug cost has limited its use to the South African private health-care 
sector and certain provinces in the public health-care sector only.  
 
Hydroxychloroquine, an antimalarial drug, may be used as monotherapy for mild RA, or in 
combination with methotrexate for moderate to severe disease [29]. In SA, chloroquine rather 
than hydroxychloroquine is available. Sulphasalazine suppresses lymphocyte and leucocyte 
functions, with down-regulatory inflammatory actions from enzymatic blockade [1]. It is 
effective in combination with methotrexate, or as monotherapy in mild RA, and useful in 
patients in whom methotrexate is contraindicated [21].  
 
Biologic DMARDs are proteins directed against specific cytokines or their cell receptors [21, 
29]. They are classified into drugs that inhibit TNF-α (Infliximab, Etanercept, Adalimumab) 
and drugs targeting cytokines or B-cells other than TNF (Abatacept, Rituximab, 
Tocilizumab) [21]. Biologic DMARDs are indicated in patients with a poor response to 
synthetic DMARDs, or in patients with high disease activity, or moderate disease activity 
with poor prognostic factors (seropositivity, erosive disease, extra-articular disease or 
functional disability) [21].  Glucocorticoids are potent anti-inflammatory drugs that offer 
prompt and marked symptomatic relief. When used in combination with DMARD therapy in 
early RA, they inhibit the development of erosions [37]. All patients with RA are prescribed 
analgesics including non-steroidal anti-inflammatories (NSAID), on an ‘as needed’ basis, for 
symptomatic relief provided there is no contraindication to their use [21, 29].  
  
Cardiovascular disease in rheumatoid arthritis   
Epidemiology  
 
Cardiovascular disease carries a higher mortality in developing countries than developed ones 
[38]. According to the World Health Organisation (WHO) in 2001, CVD accounted for 9.2% 
of total deaths in Africa, compared to 31% in the developed world [39]. Africa has the lowest 
global output of cardiovascular research [40], and there is paucity of studies exploring CVD 
in patients with RA in Africa and SA.  
 
The incidence of cardiovascular events in patients with RA occurs three times more 
frequently than in the general population [6]. Accelerated coronary artery atherosclerosis is 
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associated with increased mortality in RA [23]. This excess mortality is more pronounced in 
studies of RA populations with longer disease duration than in cohorts with early RA [41]. 
The global Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis 
Program (QUEST-RA) study, with a cohort of 4363 patients, conducted between 2005-2006, 
found an overall prevalence of cardiovascular morbidity of 9.3%. There was considerable 
variation between countries, with the highest prevalence in the United States of America 
(USA), United Kingdom (UK), Poland and Germany, and the lowest in Argentina and France 
[23]. These findings were similar to the WHO multinational Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA) project [42], which found an overall 
prevalence of lifetime myocardial infarction (MI) of 3.2%, and stroke of 1.9% [23]. Further, 
cardiovascular events were more prevalent in men than women and occurred approximately a 
decade earlier in patients with RA, than the general population, suggesting that RA is an 
independent risk factor for premature ischaemic heart disease (IHD) [22]. In keeping with 
this, a recent 15-year prospective cohort study, Dutch patients with RA had a 54% higher risk 
of mortality compared to the general Dutch population, with the last three years of study 
showing an equal mortality risk between the two groups, a trend likely attributed to effects of 
treatment intensification in the last decade [43]. 
 
Prevalence of traditional cardiovascular risk factors extrapolated from the QUEST-RA study, 
were hypertension (33%), dyslipidaemia (14%), diabetes mellitus (DM) (8%), smoking 
(43%), physical inactivity (72%) and obesity (18%). Diabetes mellitus and smoking were 
both more common in men than women. Additionally, extra-articular disease was 
significantly associated with cardiovascular morbidity [23].  
 
Rheumatoid arthritis increases the lifetime risk for CAD two fold compared to the general 
population, and this risk is of equal magnitude to patients with DM [44, 45]. In order to 
correctly reflect the increased risk of heart disease in patients with RA, the Framingham 
cardiovascular risk score, is multiplied by a factor of 1.5 in patients with RA [45]. 
Furthermore, patients with RA have a two-fold increased risk of developing heart failure. 
Seropositive disease is associated with diastolic dysfunction, with a preserved ejection 
fraction of more than 50% [44]. The outcome of patients with RA and heart failure is poorer 




A small study found an increased frequency of asymptomatic cardiac involvement in RA 
patients [46]. Based on echocardiographic findings; 37% had cardiomyopathy, 7% residual 
abnormalities of an MI, 83% valvular heart disease with mitral regurgitation being the 
dominant lesion, and 13% had pericarditis. Electrocardiogram abnormalities were found in 
63% of patients, which included left ventricular hypertrophy, sequelae of myocardial 
ischemia, first-degree atrioventricular block, right bundle branch block and right atrial 
hypertrophy [46].  
 
Traditional cardiovascular risk profile in rheumatoid arthritis   
1. Dyslipidaemia  
 
In RA, traditional cardiovascular risk factors are influenced by both inflammation inherent to 
the disease and the pharmacodynamics of anti-rheumatic drugs. Cholesterol, particularly low 
density lipoprotein (LDL), forms fatty streaks in coronary arteries, which foster flow-limiting 
atherosclerotic plaques [47]. When these plaques rupture, thrombosis ensues, leading to 
blockage of coronary arteries and an MI. Rheumatoid arthritis related dyslipidaemia is 
characterised by a low total cholesterol and HDL, and elevated triglyceride and small LDL 
[3]. During periods of high grade inflammation, there is marked suppression of total 
cholesterol, HDL and LDL levels, yielding an unfavourable pro-atherogenic ratio of total 
cholesterol to HDL [44].  
 
The total cholesterol to HDL ratio is a better CVD risk predictor in RA than individual lipid 
components [45], and studies show HDL levels are significantly lower in RA patients 
compared to matched control subjects [48]. This paradoxical relationship between 
inflammation and lipid profiles translates into increased CAD risk in RA. Inflammation in 
RA alters lipoprotein structure and function and the HDL load of serum amyloid A increases 
with a decrease in apolipoprotein A-I, leading to a shift in the anti-atherogenic effect of HDL 
to a pro-atherogenic effect [44].  
 
Further, the anti-inflammatory effects of drugs on lipid profiles are inconsistent. While there 
is evidence that hydroxychloroquine improves atherogenic lipid profiles [49], the role of 
methotrexate, the gold standard of treatment, is unclear. Tumour necrosis factor-α blockers 
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elevate both total cholesterol and HDL levels, resulting in a stable atherogenic profile while 
tocilizumab, an IL-6 inhibitor, elevates total cholesterol and LDL [47].  
 
2. Insulin resistance and diabetes mellitus 
 
Insulin resistance promotes atherosclerosis. Cytokine driven mechanisms make muscle and 
adipose tissue insulin resistant, resulting in an “inflammatory metabolic” syndrome [10]. 
Epidemiological studies show a strong association between RA and insulin resistance, and a 
study in 2004 showed a 54% risk in RA patients compared to 40% in the general population 
[50]. Furthermore, high grade inflammation is associated with significantly higher levels of 
insulin resistance. Predictors of insulin resistance included elevated CRP, ESR, IL-6, TNF-α 
and increased waist circumference [47].  
 
There is a 50% increase in the risk of DM in RA, even after controlling for glucocorticoid use 
[51]. Studies also show a decrease in insulin resistance with common DMARDs including 




Although older studies found no difference in hypertension between RA and control groups 
[47], more recent studies show that hypertension is commoner in RA [52], with up to 50% of 
RA patients being underdiagnosed and undertreated (systolic blood pressure greater than 140 
mmHg) [44, 52]. There is also a greater prevalence of diastolic hypertension, when compared 
to non RA community controls [53]. This is probably compounded by inflammation, NSAID 
and glucocorticoid use which may exacerbate hypertension in RA [44, 47]. Increased arterial 
wall stiffness seen in patients with RA, suggest a diminished ability of the arterial system to 




Obesity is defined as a body mass index (BMI) of greater than 29 kg/m
2
 by the WHO. In the 
non RA population, obesity is associated with higher CRP, and an increased cardiovascular 
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risk [54]. The prevalence of obesity is 54% higher in patients with RA than non RA control 
groups [47] and a combination of low muscle mass and high fat mass is observed in RA [44].  
  
Adipose tissue releases pro-inflammatory cytokines, IL-6 and adiponectin, thus contributing 
to low grade inflammation, and furthermore visceral adiposity in RA is associated with 
hypertension, insulin resistance and metabolic syndrome [44]. Men with RA have higher 
levels of visceral fat compared to controls, whilst women with RA had increased 
subcutaneous fat compared to controls, with a similar BMI and waist circumference [47]. 
Therefore, obesity in RA is associated with higher CRP levels and aggressive articular 
disease [47].  
 
5. Physical inactivity 
 
Physical activity is an important modifiable risk factor of CVD. Rheumatoid arthritis patients 
are significantly less physically active than population based controls, due to a combination 
of uncontrolled inflammation, low muscle mass, increased body fat composition, and 
limitations of joint movement from poor disease control. Physical inactivity, as in the general 
population, leads to hypertension and dyslipidaemia, which portends an unfavourable 
cardiovascular profile [47].  
 
6. Cigarette smoking  
 
Cigarette smoking is one of the most prominent modifiable risk factors for CVD and is also 
one of the strongest known environmental risk factor for RA [47]. Recent case controlled 
studies show a higher prevalence of current or past cigarette smoking observed in RA patients 
[47]. Smoking is associated with higher disease activity, extra-articular disease, accelerated 
atherosclerosis and multi-vessel coronary artery calcification [55, 56]. The Multiple Risk 
Factor Intervention Trial (MRFIT) found that smokers had twice the number of coronary 
heart disease deaths compared to non-smokers. Additionally, a strong association between 
CRP and subsequent risk of cardiovascular deaths is seen in cigarette smokers independent of 





7. Menopause   
 
Oestrogen has a modulatory effect on endothelial function and vascular tone. It mediates the 
release of vasodilators (nitric oxide and prostacyclin), and inhibits the production of 
vasoconstrictors (endothelin and angiotensin II) [58-60]. Further it has an anti-inflammatory 
effect, and reduces the secretion of TNF-α, a pro-atherogenic cytokine [60].  
  
In a large prospective cohort of pre- and post-menopausal women, the risk of MI was 
significantly increased in participants with RA compared with those without RA [58]. The 
risk of CVD increases significantly after menopause due to lower levels of oestrogen, and is 
the leading cause of morbidity and mortality in these patients [59, 60]. Post menopause, there 
is a doubling of mortality both for CAD and stroke, for every 20 mmHg systolic and 10 
mmHg diastolic blood pressure increase above normal [61]. The risk is higher in women with 
premature menopause i.e. 40 years and younger [60].  
  
Hormone replacement therapy (HRT) has a cardio-protective effect evident by a reduction in 
LDL cholesterol, increases in HDL cholesterol, maintenance of endothelial cell integrity and 
promotion of nitric oxide production [60, 62, 63]. Use of HRT in RA has significant 
ameliorating effects on inflammation and joint destruction [64], however studies on its 
influence on CVD risk in RA are unknown.  
  
Rheumatoid arthritis as an independent risk factor for cardiovascular disease   
 
There is mounting evidence that the increased cardiovascular morbidity and mortality in RA 
is due to the pro-atherogenic changes seen with systemic inflammation rather than it being 
due to traditional CVD risk factors only (Figure 2) [44, 52, 65, 66]. This has resulted in the 
recognition of RA as an independent CVD risk factor [23, 67].  
 
Rheumatoid arthritis is associated with a doubling of risk for MI and stroke, and a 30% 
increase in CVD associated death [67, 68]. In 50% of RA patients with confirmed IHD have 
clinically silent disease [52]. Further, the 30 day mortality following a MI or stroke is higher 
amongst patients with RA compared to non RA controls [67]. The relative risk for 
cardiovascular events in patients with RA is highest among young patients, with an increase 
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in absolute events greatest amongst older patients [67]. In a case control study of 76 RA and 
641 non RA patients, a significantly higher prevalence of CAD, stroke, higher diastolic blood 
pressure (BP), significantly less HDL cholesterol and higher LDL cholesterol was found in 
the RA cohort [53, 69].  
 
 
Figure 2. Determinants of heart disease in patients with rheumatoid arthritis  
compared to the general population [44] 
 
Endothelial dysfunction, an integral step in atherogenesis, is related to inflammation, from 
chronic cytokine release from inflamed joints in RA [70-72], and HLA-DRB1 expression 
[73]. Studies show that HLA-DRB1, promotes survival of autoreactive T-cells, which 
mediate chronic inflammation [44]. These T-cells play a role in atherosclerotic plaque 
formation by producing cytokines and damaging vascular smooth muscle cells [44]. 
Therefore the HLA-DRB1 gene is associated with an increased risk of MI and other non-RA 
associated heart disease [74-76]. Supporting evidence of this effect has been shown in the use 
of T-cell inhibiting drugs currently used in percutaneous drug eluting stents in CAD, thereby 
preventing in-stent stenosis [44]. So compelling is atherogenesis a precocious feature in RA, 
that it is labelled an extra-articular manifestation of the syndrome, and defined in some 




Studies in the Pima Indians of Arizona, USA who have the highest prevalence of RA in the 
world, found the presence of swollen, tender joints was a predictor of cardiovascular 
mortality independent of traditional cardiovascular risk factors [74]. The rheumatoid joint 
synovial tissue releases in abundance TNF-α, IL-6 and IL-1, which alters the function of 
adipose tissue and vascular endothelium [3, 79-82]. These changes produce dysregulation in 
glycaemic control, lipid profiles and endothelial function [3]. The Physicians Health Study, in 
the general population, found higher IL-6 levels in men who experienced their first MI, 
compared to those who remained CVD free during a six year follow up [83]. This highlights 
the atherogenic role of IL-6 [6]. 
 
B-cells are important contributors to the immunopathogenesis of RA and RF production. 
Seropositive disease confers an excess risk in cardiovascular morbidity and mortality [45] 
and both anti-CCP antibodies and extra-articular disease are independently associated with 
the development of IHD and an increased mortality from CAD respectively [23, 41]. Dessein 
et al. showed that in RA patients, a low glomerular filtration rate (GFR) and RF seropositivity 
were independent predictors of endothelial dysfunction [72]. Autopsy cases showed that in 
RA patients, the coronary plaque comprised exclusively of B-cells, compared to the general 
population, where lymphocytic infiltrates in CAD consists exclusively of T-cells [82]. This 
reinforces the implication that RA is an independent risk factor for CVD.  
 
Higher levels of CRP are risk predictors of CAD and it follows, that chronic inflammation, as 
occurs in RA, could herald premature atherosclerosis as inflammatory cells have been found 
in atherosclerotic plaque [79, 80].The role of CRP in clotting and thrombosis is related to its 
increased activity of tissue factor [81]. A prospective study of subjects without clinical CVD, 
found that elevated CRP, was an independent predictor of cardiovascular events, both for MI 
and MI related deaths. This association is stronger in women than men [57]. 
 
Carotid artery intima thickness, is a marker of early atherosclerosis, and is increased in 
patients with RA [84, 85]. Shared mechanisms of immunological disease, systemic 
endothelial activation and circulating immune complexes lead to increased pro-thrombotic 
markers and increased arterial stiffness in RA [86]. The prevalence and severity of coronary 
calcification is increased in patients with established RA, and is associated with elevated 




Studies show a positive relationship between cardiovascular biomarkers and active RA which 
is associated with consistently reduced HDL levels, leading to an unfavourable lipid profile 
[87, 88]. Bony erosion, a sequelae of persistent inflammation, occurs in 80% of patients 
untreated or inadequately treated within one year following diagnosis [10], and predicts 
cardiovascular events and mortality in RA [41]. Further the QUEST-RA study, supports the 
association of higher cardiovascular morbidity with severe RA [23] and recent studies 
suggests CVD risk for patients with RA in remission is similar to non RA controls [89]. 
Cardiovascular risk increases by 7% for each additional RA acute flare [89, 90]. This 
highlights the concept of accumulating cardiovascular damage with each acute flare, and 
possibly explains the excess cardiovascular risk in RA patients compared to non RA controls.  
 
Role of pharmaco-therapeutics in rheumatoid arthritis and effects on cardiovascular 
risk 
  
Disease modifying anti-rheumatic drugs, apart from their inflammatory ameliorating effects, 
also decrease atherosclerosis risk and have proven beneficial effects on RA associated CVD 
[41].  
 
Methotrexate is associated with a 21% reduction in cardiovascular events [44]. In a small 
study of 22 patients with RA, 14 patients who commenced methotrexate had a decrease in 
insulin resistance during the first eight weeks [91]. In contrast, other studies show an 
increased prevalence of homocysteinaemia, an independent risk factor for CVD, in RA 
patients on methotrexate therapy [92].  
 
Other traditional DMARDs may also decrease cardiovascular risk; hydroxychloroquine 
improves lipid profiles, with a reduction in LDL, and total cholesterol/HDL ratio [44, 93], 
and decreases the risk of DM in patients with RA [44]. Newer therapies, example TNF-α 
inhibitor therapy are associated with reduced risk of all heart disease events [44], and they 
have a favourable effect on HDL lipid profiles [94], with improved endothelial function and 
insulin resistance [44].  
 
There is conflicting data on the use of glucocorticoids. Older studies showed that 
glucocorticoid use resulted in hypertension, decreased insulin sensitivity, elevated lipid 
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levels, and increased carotid plaque and arterial stiffness [95]. Doses of greater than 7.5 mg 
per day appear to have twice the risk of heart disease compared to those who did not receive 
glucocorticoids [96], however, the QUEST-RA study showed that the fundamental effects of 
lowering inflammatory burden, correlates with an independent association of long-term 
glucocorticoid use and a reduced risk of all cause cardiovascular events [23]. Additionally, 
the benefit of reducing high-grade inflammation in an acute flare may counteract the adverse 
cardiovascular effects of glucocorticoid use [45].  
 
In contrast, both selective and non-selective NSAIDs are known to cause clinically 
significant hypertension, which may require treatment [97], and even small increases of 5 
mmHg in diastolic BP confer a 15% increase in cardiovascular event risk [98].  
 
Cyclooxygenase inhibitors, in particular, through renal prostaglandin inhibition, exacerbate 
fluid retention and aggravate hypertension [99]. The use of NSAIDs and its association with 
cardiovascular risk was brought to the fore in the Vioxx Gastrointestinal Outcomes Research 
(VIGOR) study. An increased risk of heart disease was found with rofecoxib use [100]. A 
meta-analysis has shown no differences in heart disease events with celecoxib or ibuprofen 
use, and naproxen conferred the lowest cardiovascular risk [101], with the added benefit of 
possible aspirin-like antiplatelet cardio-protective effects [102].  
  
Cardiovascular risk assessment in rheumatoid arthritis   
 
There are several validated cardiovascular risk assessment tools available for use, including 
the Framingham Risk Score (FRS), and the Systematic Coronary Risk Evaluation Score 
(SCORE), which determines the 10-year risk of fatal CVD (Table 4). Additionally, tools like 
the Reynolds Risk Score (RRS) takes into account traditional risk factors as well as the added 
risk of inflammation, in identifying the 10-year risk for a MI or stroke. The QRISK3 score 
developed in 2017 includes additional CVD risk factors chronic kidney disease, presence of 
RA and regular glucocorticoid use.  
 
All of these CVD risk models have been developed based on data primarily from white men 
and women from developed countries, with little validation for multi-ethnic populations [103, 
104]. Both the FRS and RRS were developed and validated in USA, SCORE in Europe and 
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QRISK3 in the UK, and their adaptability to developing countries, particularly an African 
ethnically diverse population has not been validated [105]. 
 
Studies show that traditional risk factors account for only a portion of the overall risk for 
CVD in RA, with the additional risk attributed to inflammation [65, 66]. Therefore the lack of 
recognition of inflammatory markers in FRS and SCORE, underestimates the cardiovascular 
risk in RA. An expert panel convened by EULAR, recommends a multiplier of 1.5 for FRS 
and SCORE if a patient fulfils two or more of the following: RA disease duration more than 
10 years, RF or anti-CCP antibody positivity, or extra-articular manifestations [45, 47].  
 
The most prevalent conventional CVD risk factors reported in limited South African RA 
studies are hypertension and dyslipidaemia [106]. A local study by Solomon et al. highlighted 
the need for population specific CVD risk stratification, concluding that individual CVD risk 
factors are consistently and independently related to atherosclerosis in South African White 
but not South African Black patients with RA [107]. The impact of urbanisation translates 
into different evolving CVD risk profiles with consequent altered CVD presentations [108]. 
Studies in Africa show that obesity is associated with hypertension as well as diastolic heart 
failure and systemic inflammation [109, 110]. Recent studies in the South African Black 
population show the prevalence of all major traditional CVD risk factors are high and 
increasing [111-113], with South African Black women sustaining higher obesity rates than 
other local South African ethnic groups [114]. Black South Africans with RA smoked less 
frequently, but had more prevalent hypertension, DM, with lower total cholesterol and HDL 
cholesterol concentrations compared to other South African ethnic groups with RA [107]. 
Further, the overall metabolic risk burden was similar in South African Black compared with 
South African White, Asian and Mixed Ancestry patients with RA [106]. The Framingham 
score correlated with atherosclerosis in South African White but not Black patients, 
underscoring the limitations of adequate cardiovascular risk assessment in Africans with RA 
[107].    
       
With no current national guidelines, CVD risk assessment in clinical practice in SA is 




Table 4. Comparison of clinical variables and risk outcomes in the Framingham Risk Score, 
Reynolds Risk Score and Systematic Coronary Risk Evaluation Score [47] 
  
 




A fundamental principle linking RA to CVD is the shared inflammation. Studies suggest that 
patients with RA are less likely to receive primary or secondary heart disease screening or 
preventions [44]. Therefore understanding the cardiovascular risk in a patient with RA 
requires a revolutionary conceptual model that highlights the overlapping influence of 
traditional risk factors and inflammation.  
 
In SA, life expectancy has increased to 62 years according to WHO 2015 statistics, and with 
increased longevity following a decline in communicable diseases (HIV), it is expected that 
the burden of non-communicable diseases, including RA, will increase [115].  
 
Studies with non RA control groups show that the lifetime risk for CAD in RA patients is of 
equal magnitude to the general population with DM [44, 45]. In the non RA population, 
obesity is associated with higher CRP, and an increased cardiovascular risk [54]. Recent 
studies show that hypertension is commoner in RA compared to community control groups 
[52]. In developing countries, 46.7% of CVD deaths in the general population occur below 
the age of 70 years. Case control comparison of incident acute MI cases and age and sex 
matched controls revealed the most important predictors of acute MI were current smoking, 
hypertension, DM, and abdominal obesity [38]. The expectations in RA patients, is that these 
traditional CVD risk factors prevalent in the general population, are common, however, their 
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CVD risk may be enhanced due to the added deleterious influences of inflammation and 
effects of joint targeted therapy.  
  
Cardiovascular risk management in patients with RA requires an evaluation of biomarkers, 
control of traditional risk factors, and RA disease control. Early control of disease activity in 
RA predicts significant survival benefits. Current therapeutic strategies for the management 
of RA in SA are outlined by the SARAA [21]. Treatment of dyslipidaemia is based on 
cardiovascular risk using the Framingham Risk Score [116], with percentage risk multiplied 
by 1.5 in the setting of RA with seropositivity, extra-articular or established disease [21, 47]. 
Improved RA disease control, with methotrexate and anti-TNF therapy, decreases CVD risk 
in RA patients. However, no population specific CVD risk factor surveillance guidelines are 
currently in use locally.  
 
A robust preventative strategy of CVD in this high-risk group is required. This study will 
improve our knowledge of CVD burden and risk in RA in our setting, and study results can 
be applied to developing a framework for risk assessment and health care targets in this 
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Cardiovascular disease (CVD), as a driver of morbidity and mortality in rheumatoid arthritis 
(RA), is well described in developed countries, with limited studies from developing 
countries especially Africa.  
  
Objective:  To describe the prevalence of CVD and traditional CVD risk factors in patients 
with established RA, and the relationship between RA disease activity and CVD.  
 
Methods: A retrospective chart review was conducted of all patients diagnosed with RA, 
according to the American College of Rheumatology classification criteria, attending a 
regional level arthritis clinic. Demographic data, RA disease profile, Simplified Disease 
Activity Index (SDAI) and Health Assessment Questionnaire (HAQ) scores, CVD risk 
factors, electrocardiogram (ECG), echocardiogram and laboratory findings were recorded on 
a standard data form.  Continuous variables were compared using Student T-test, and 
categorical variables were compared using Pearson Chi Squared test and Fischer’s test as 
appropriate. Relative risk was calculated to determine a difference in prevalence of CVD 
between age groups and gender. A one way analysis of variance was used to determine the 
difference between CVD risk assessment scores.  
 
Results: One hundred and fifty patients with RA met the inclusion criteria; of which 24 had 
CVD. Patients with CVD were older compared to those without CVD (63.4 ± 9.3 years vs 58 
± 11.7 years, p = 0.02). Whilst a lower relative risk of CVD was observed in patients younger 
than 50 years (RR = 0.352), the relative risk of CVD was higher in men compared to women 
(RR = 2.039). Indian patients were more likely to have CVD compared to both Black (p = 
<0.0001) and White patients (p = 0.0023).  
 
No difference in seropositivity (p = 0.516), HAQ (p = 0.349), SDAI (p = 0.891), or 
radiological involvement was observed. Extra-articular disease was significantly more 
common among patients with CVD (p = 0.0002), whilst in contrast prolonged early morning 
stiffness was observed significantly more frequently in patients without CVD (p = 0.0016). 
Diabetes mellitus (p = 0.0018), dyslipidaemia (p = 0.0026) and chronic kidney disease (p = 
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0.0013) was more common in patients with CVD. Patients without CVD were more 
physically inactive (p = 0.0001) and obese (p = 0.005), whilst patients with CVD were 
overweight (p = 0.0293). Women with CVD were more likely menopausal (p = <0.0001), and 
on hormone replacement therapy (p = <0.0001).  
 
In patients without CVD, subclinical CVD was evident in 25% of 105 ECGs, and 58% of 104 
echocardiograms reviewed. Differences between CVD risk assessment scores at different 
levels of risk were observed (p = <0.0001). 
 
Conclusion: The burden of traditional CVD risk factors in RA is high, and CVD in RA is 
associated with an ethnic, age and gender differential. Whilst coronary artery disease was the 
most common CVD in RA patients, echocardiographic evidence of subclinical cardiac 
disease in RA seems common. No correlation was observed between RA disease activity and 
CVD in RA. A discriminant CVD risk assessment score is needed in a multi-ethnic South 
African population with RA.  
 





Rheumatoid arthritis (RA) is a common chronic systemic autoimmune inflammatory disease, 
characterized by symmetrical polyarthritis, with extra-articular manifestations [1]. The 
mortality risk in RA is increased by 70% compared to the general population [2], and the 
leading cause of death in RA is cardiovascular disease (CVD) [2, 3]. Both traditional and 
non-traditional factors combine to increase the adverse cardiovascular risk profile in patients 
with RA, with CVD deaths occurring 5 - 10 years prematurely compared to the general 
population [4].   
 
The global prevalence of CVD morbidity in RA is 9.3%, with a wide geographic variation; 
the highest prevalence in Germany (17.8%), followed by Poland (11.8%), and the lowest in 
France (3.6%) [5]. There are however limited studies on the prevalence of CVD in RA 




Traditional CVD risk factors (hypertension, diabetes mellitus (DM), dyslipidaemia, obesity, 
physical inactivity and smoking) play a causal role in 50% of all coronary artery disease 
(CAD) in the general population [6]. In RA, traditional CVD risk factors are influenced by 
both inflammation inherent to the disease, and pharmacodynamics of anti-rheumatic drugs, 
yielding an unfavourable pro-atherogenic profile [7]. Mounting evidence recognises RA as an 
independent risk factor for CVD [5, 8].  
  
Systemic inflammation results in an “inflammatory metabolic syndrome”[9] and vascular 
endothelial dysfunction [3], which promote accelerated atherosclerosis [7]. Rheumatoid 
arthritis seropositivity [10], high disease activity and presence of extra-articular disease 
confer an excess CVD mortality risk [5]. Disease modifying anti-rheumatic drugs (DMARD), 
non-steroidal anti-inflammatory drugs (NSAID) and glucocorticoids effect fundamental 
changes in traditional CVD risk factors and all cause cardiovascular event risk in RA [5, 11].  
 
Several CVD risk assessment tools (Framingham Risk Score (FRS) and the Systematic 
Coronary Risk Evaluation Score (SCORE)) are validated for CVD risk prediction in the 
general population [12, 13]. Their performance accuracy in the RA population is poor [14], 
and recognition of the additional CVD risk attributed to inflammation in RA, has led to the 
modification of the FRS to be multiplied by 1.5 in RA patients who fulfil two or more of the 
following: RA disease duration more than 10 years, seropositive disease, or presence of 
extra-articular manifestations [15]. Other scoring tools recognising the added risk of 
inflammation includes the Reynolds Risk Score and the QRISK3 score [15]. However these 
scoring models are country and population specific, with poor reliability in diverse multi-
ethnic populations as in South Africa (SA).  
 
There are limited studies describing the cardiovascular profile of patients with RA from SA. 
Solomon et al. highlighted the need for population specific CVD risk stratification, 
concluding that individual CVD risk factors are consistently and independently related to 
atherosclerosis in South African White but not Black patients with RA [16]. The impact of 
urbanisation translates into different evolving CVD risk profiles with consequent altered 
CVD presentations [17]. Recent studies in the South African Black population show a high 
burden of traditional CVD risk factors [18-20], with South African Black women having a 
much higher rate of obesity than other local South African ethnic groups [21]. A study in 
Johannesburg found that Black South Africans with RA smoked less frequently, but had more 
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prevalent hypertension, DM, with lower total cholesterol and high density lipoprotein (HDL) 
cholesterol concentrations compared to other South African ethnic groups with RA [16]. 
Overall metabolic risk burden was similar in South African Black compared with South 
African White, Asian and Mixed Ancestry patients with RA [22]. The Framingham score 
correlated with atherosclerosis in South African White but not Black patients, underscoring 
the limitations of adequate cardiovascular risk assessment in non-White Africans with RA 
[16]. 
 
There are limited studies on the prevalence, traditional risk factors and relationship to disease 
activity of CVD in RA patients from sub-Saharan Africa. With the predicted increase in 
longevity and non-communicable diseases, it is critical that valid, reliable tools for assessing 
10 - year CVD risk be developed to manage CVD risk in RA patients, and thereby favourably 




Ethical approval for the study was granted by the Biomedical Research Ethic Committee of 
University of KwaZulu-Natal (UKZN) (BREC Ref No.: BE 535/17) and the KwaZulu-Natal 
(KZN) Provincial Department of Health, King Edward VIII Hospital (KEH) and the arthritis 
clinic.  
 
A retrospective, descriptive chart review was conducted in the arthritis clinic of KEH, a 
tertiary public hospital in KZN. The arthritis clinic is a dedicated weekly run rheumatological 
service, under the stewardship of a team comprising a rheumatologist, general physicians and 
medical officers. Patients with RA are reviewed on a four monthly basis or sooner if they 
have complications or are newly commenced on DMARDs. Majority of patients attending the 
clinic are of Black and Indian ethnicity, reflecting the population demography of KZN, and 
the majority of the population utilising the public health-care system in KZN.  
  
A chart review of all patients with a clinical diagnosis of RA was conducted between August 
2017 and March 2018. Study inclusion criteria were a minimum of six months disease 
duration, age of 18 years or older, confirmed diagnosis of RA according to the American 
College of Rheumatology classification criteria 1987/2010 [23, 24] and attendance at the 
clinic in the last six months. Patients with concomitant connective tissue diseases, or other 
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forms of arthritis were excluded. A total of 162 files were reviewed, of which 12 were 
excluded due to missing data and/or a diagnosis of coexisting connective tissue disease. 
Patients with established cardiovascular disease in this study included CAD, valvular heart 
disease, cardiomyopathy, dysrhythmia and pericardial disease. Cardiovascular disease was 
not based on echocardiogram findings. 
 
Demographic data (age, gender, ethnicity, residence, education level, employment history), 
duration of disease, extra-articular manifestations, underlying cardiovascular risk factors 
(DM, hypertension, dyslipidaemia, physical activity, smoking history, menopausal status, 
chronic kidney disease (CKD), history of cerebrovascular accident (CVA) and human 
immunodeficiency virus (HIV) infection), presence of established CVD, rheumatoid factor 
(RF)/anti-cyclic citrullinated peptide (ACCP) positivity, health assessment questionnaire 
(HAQ) score, simplified disease activity index (SDAI), radiological involvement and drug 
therapy were extrapolated from medical records. Radiographs performed within the 
preceding twelve months of study were analysed. The presence of osteoporosis was recorded 
from available dual energy X-Ray absorptiometry (DEXA) scans in medical records. Blood 
pressure (BP), weight and height as recorded in the last visit, was documented. Weight and 
height were used to calculate the body mass index (BMI) (weight/height
2
), which were 
categorised according to the World Health Organisation (WHO) classification of obesity viz. 
underweight (<18.5 kg/m
2
), normal (18.5-24.9 kg/m
2
), overweight (25-29.9 kg/m
2
), obese 
Class I (30-24.9 kg/m
2
), obese Class II (35-39.9 kg/m
2
), and obese Class III (> than 40 
kg/m
2
) [25].   
 
Physical activity was categorised according to the 2016 European Society of Cardiology 
(ESC) guidelines on CVD prevention in clinical practice [26]. Categories are grouped 
according to the metabolic equivalent i.e. energy cost of a given activity divided by the 
resting energy expenditure viz. nil (no physical activity), light (light household work), 
moderate (cycling or brisk walking) and vigorous (jogging or swimming or running). These 
categories of physical activity have been validated in several studies, and are incorporated as 
part of ESC recommendations for CVD prevention [27-29]. 
  
The HAQ functional assessment is widely used in RA and has been validated in several 
studies, such as prediction of successful aging, inversion of the therapeutic pyramid in RA, 
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and examination of mortality risks in RA, work capacity and performance, occupation and 
the ability to live independently [30]. 
 
The SDAI combines the sum of tender and swollen 28 joint count, patient and doctor global 
assessment and acute phase reactants. This composite index has been validated in multiple 
studies in RA, correlating with function and radiographic changes [31-34].   
 
Electrocardiogram (ECG) and echocardiogram findings (performed within the preceding 
year) were recorded. The annual haemoglobin, estimated glomerular filtration rate, C reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) as at last visit, and the glycated 
haemoglobin (HbA1C) and lipid studies (done within the preceding year) were recorded. It 
must be noted that a paradoxical relationship between inflammation and lipid profiles occurs 
in RA which translates into a CAD risk factor. Inflammation in RA alters lipoprotein 
structure and function and the HDL load of serum amyloid A increases with a decrease in 
apolipoprotein A-I, leading to a shift in the anti-atherogenic effect of HDL to a pro-
atherogenic effect [35]. 
   
Deidentified data was entered into an Excel spreadsheet. Data analysis was conducted using 
SPSS version 25 (IBM SPSS Statistics for Windows, version 24.0. Amonk, NY:IBM Corp.) 
Continuous variables such as age, disease duration, BMI, amongst others, were summarised 
as mean (standard deviation (SD)). Categorical variables were summarised using proportions 
and percentages. Continuous variables were compared using student t-test, and categorical 
variables were compared using Pearson Chi Squared test and Fischer’s test as appropriate. 
Regression analysis was done to explore independent association of age and gender in 
relation to CVD.  Relative risk was calculated to determine a difference in prevalence of 
CVD between age groups and gender.  
  
Predicted 10 year CVD risk was calculated for patients without CVD. Algorithm derived 
scores were divided into three categories viz. low risk (<10%), intermediate (10-19%) and 
high risk (>20%), stratifying patients who are eligible for blood pressure and lipid lowering 
therapies [36, 37]. Statins are advised in high risk patients, and conditionally initiated in 
patients with intermediate risk i.e. low density lipoprotein (LDL) >3.5 mmol/L or 
apolipoprotein B >1.1 g/L, or men older than 49 years or females older than 59 years with 1 
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risk factor (low HDL, impaired fasting glucose, increased waist circumference, smoker, or 
hypertension).  
  
Risk assessment models evaluating different parameters were applied viz. Framingham, 
modified Framingham, QRisk3 and Reynolds risk score (Table 1).  
 
The Framingham and Reynolds scores have Class I recommendations from the American 
College of Cardiology and the American Heart Association [38]. The modified Framingham 
score is a validated RA-specific risk prediction algorithm incorporated in European League 
Against Rheumatism (EULAR) guidelines on CVD risk management in patients with RA 
[39, 40]. The QRISK3 score has been validated in comparative prospective cohort studies 
[41, 42]. A one way analysis of variance (ANOVA) was used to determine if there was a 
statistical significant difference between various CVD risk assessment scores. In the event of 
a positive ANOVA, a post hoc test such as Tukeys was used to conduct a pairwise 
comparison of these scores. Statistical significance was set at p < 0.05. 
  
Table 1. Comparison of clinical variables in the Framingham Risk Score, Modified 
Framingham Risk Score, Reynolds Risk Score and QRISK3 Score [15, 39, 42] 
Clinical variable FRS Modified 
FRS 
RRS QRISK3 
Age          
Gender         
Total cholesterol         
High density lipoprotein         
Current smoker         
Systolic blood pressure         
On medication for hypertension        
C reactive protein      
Mother or father with heart 
attack or stroke before age 60  
      
Rheumatoid arthritis       
Glucocorticoid use      
Ethnicity      
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Diabetes mellitus      
Chronic kidney disease      
Height      




Demographic profile  
  
The mean age of the study group was 58.9 ± 11.5 years, with a range of 24 to 87 years, and a 
female to male ratio of 9:1 (Table 1). Majority of patients were Indian 78 (52%), followed by 
Blacks 63 (42%), with Whites and Coloureds comprising 8 (5.3%) and 1 (0.7%) respectively.  
 
Of the total cohort of 150 patients, CVD was present in 24 patients (16%), with majority 
having CAD 18 (75%) followed by small numbers having  valvular heart disease 2 (8.3%), 
cardiomyopathy 2 (8.3%), dysrhythmia 1 (4.2%), and pericardial disease 1 (4.2%).  
 
Patients with CVD were significantly older compared to patients without CVD (63.4 ± 9.3 
years vs 58.0 ± 11.7 years, p = 0.02). A lower relative risk (RR) of CVD was observed in 
patients younger than 50 years (RR = 0.352).  
 
Women with CVD, constituted 14.2 % of the total female cohort, and the majority in the 
CVD cohort (79%), however a higher RR of CVD was observed in men compared to women 
(RR = 2.039).  
 
Cardiovascular disease was more common in Indian and White patients (p = 0.04, p = 0.07 
respectively), and Black patients were less likely to have CVD (p = 0.0015). Albeit a small 
sample size, Indian patients formed the majority of patients in the CVD group (70.8%) and 
were significantly more likely to have CVD compared to both Black (p = <0.0001) and White 
(p = 0.0023) patients.  
There was no difference in housing or educational level between patients with and without 
CVD, however patients who have never been employed were less likely to have CVD, and 
this approached statistical significance (p = 0.05).    
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Table 1. Comparison of the demographic profile of rheumatoid arthritis patients with 












Age, years 58.9 ± 11.5 63.4 ± 9.3 58.0 ± 11.7      0.02 
Gender 
        Male 














        Black 
        Indian 
        White 






















        Urban 













Level of education* 
        None 
        Primary school 
        High school 






















        Never employed 
        Unemployed 
        Informal sector 





















Continuous variables presented as mean ± standard deviation 






Rheumatoid arthritis disease activity  
   
The mean duration of disease in the total cohort was 15.4 ± 10.3 years with no significant 
difference between the two groups (Table 2). Patients without CVD had significantly longer 
duration of early morning stiffness compared to patients with CVD (25 ± 19.6 minutes vs 
53.7 ± 71.7 minutes, p = 0.0016), however the presence of extra-articular disease was more 
common in patients with CVD (83.3% vs 41.3%, p = 0.0002). The most common extra-
articular features recorded in this study were anaemia 24 (16%), osteoporosis 20 (13.3%), 
atherosclerosis 19 (12.7%) and subcutaneous nodules 15 (10%), with no significant 
differences in occurrence of individual extra-articular features between the two groups, 
probably due to the small sample size. It must be noted that due to limited access to DEXA 
scans in KZN, not all patients in this study had a DEXA scan. This potentially underestimates 
the true number of patients with osteoporosis.  
 
Atherosclerosis included all patients known with cerebrovascular accidents, peripheral 
vascular disease and computed tomography evidence of a calcified aorta and peripheral 
vascular calcification, and all these conditions were considered an extra-articular feature in 
this study. Atherosclerosis was present in 50% of RA patients with CVD (12 of 24), 
compared to 6% (7 of 126) of RA patients without CVD. In isolation, this extra-articular 
manifestation would bias one to the likelihood of CVD, however in this study, atherosclerosis 
didn’t occur as a lone extra-articular manifestation in many patients, but also other extra-
articular features were present eg. nodular disease and anaemia, so it’s significance cannot be 
ascertained with certainty. Additionally due to small sample size, comparison of 
atherosclerosis between the two groups is limited. 
 
There was no significant difference in seropositivity, disease activity scores (SDAI/HAQ), 
inflammatory markers (CRP/ESR) and radiological involvement between the two groups 








Table 2. Comparison of rheumatoid arthritis disease profile and activity in patients with 












p value  
Disease duration, years 15.4 ± 10.3 15.3 ± 11.4 15.5 ± 10.1 0.946 
Seropositive disease 114 (76.0) 17 (70.8) 97 (77)    0.516 
Early morning stiffness, minutes 49.1 ± 67.6  25 ± 29.6      53.7 ± 71.7 0.0016 
Extra-articular disease   72 (48.0)     20 (83.3)      52 (41.3) 0.0002 
SDAI 16.3 ± 12.9 15.9 ± 14.7 16.4 ± 12.6 0.891 
HAQ 0.9 ± 0.8 0.7 ± 0.8 0.9 ± 0.8 0.349 
CRP, mg/L 14.6 ± 24.3 22.0 ± 31.6 19.4 ± 19.2 0.6999 
ESR, mm/hr 47.0 ± 36.5 49.8 ± 46.7 46.5 ± 34.5 0.746 
Radiological involvement 
         Normal 
         Juxta-articular osteopaenia 
         Joint space narrowing 
         Erosive disease 

























Continuous variables presented as mean ± standard deviation, SDAI=simplified disease 
activity index, HAQ=health assessment questionnaire, CRP=C reactive protein, 
ESR=erythrocyte sedimentation rate 
 
Pharmaco-therapeutic profile of rheumatoid arthritis patients   
 
The majority of patients in the total cohort were on DMARD therapy (94.7%). Reasons for 
the eight patients not being on therapy included disease remission and previous drug 
intolerance with patient preference to remain on NSAIDs only. There was no significant 
difference in the number of DMARDs patients were on or the use of methotrexate, 
chloroquine or oral glucocorticoid between patients with or without CVD, however patients 
using sulphasalazine were more likely to have CVD (Table 3). Traditional NSAIDs were 
used by 72% of the total cohort. 
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      None  
      Methotrexate 
      Sulphasalazine 
      Chloroquine 
Number of 
DMARDs 
      Single 
      Double 





































Oral glucocorticoid   109 (72.6)      18 (75.0)     91 (72.2)       0.779 
NSAID     108 (72)      15 (62.5)     93 (73.8)       0.260 
DMARD=disease modifying anti-rheumatic drug, NSAID=non steroidal anti-inflammatory 
drug 
 
Traditional cardiovascular risk factors  
 
Patients with CVD were significantly more likely to have DM, dyslipidaemia and CKD 
(Table 4). Although hypertension was common in the study population (58.7%), there were 
no significant differences between the two groups. 
  
An increased BMI was found in 69% of the total cohort. The mean BMI was significantly 
higher in patients without CVD (25.7 ± 4.1 kg/m
2
 vs 28.5 ± 6.2 kg/m
2
, p = 0.035) and these 
patients were significantly more likely to be obese than patients with CVD (38.3% vs 5.3%, p 
= 0.005). In contrast, patients with CVD were significantly more likely to be overweight than 




Patients without CVD were significantly more physically inactive than those with CVD 
(69.8% vs 66.7%, p = 0.0001). There was however no difference in actual measured systolic 
and diastolic BP, smoking habits, family history of CVD, haemoglobin levels, HbA1C or 
lipid profiles between the two groups.   
  
Although the majority of women in the total cohort had reached menopause (82%), there was 
a significantly higher number of post-menopausal women in the group with CVD than those 
without CVD (89.5% vs 81.7%, p = <0.0001). Furthermore, there was a significantly higher 
use of hormone replacement therapy (HRT) in this group (p = <0.0001), however these were 


























Table 4. Traditional cardiovascular risk factors comparison in rheumatoid arthritis 














Blood pressure  
       Systolic, mmHg 
       Diastolic, mmHg 
88 (58.7) 
 
134.7 ± 20.8 
70.7 ± 13.2 
17 (70.8) 
 
130.3 ± 21.4 
68.6 ± 12.6 
71 (56.3) 
 
135.5 ± 20.7 





Diabetes mellitus 24 (16.0) 9 (37.5) 15 (11.9) 0.0018 
Dyslipidaemia 29 (19.3) 10 (41.7) 19 (15.1) 0.0026 
Cerebrovascular accident        5 (3.3)         0 (0.0)       5 (4.0)         - 
Chronic kidney disease 41 (27.3) 13 (54.2) 28 (22.2) 0.0013 
HIV 7 (4.7) 1 (4.2) 6 (4.8) 0.899 
Body mass index * 
       Underweight 
       Normal 
       Overweight 
       Obese 











       1 (5.26) 














       Nil 
       Light 
       Moderate 




















         - 
Smoking 
       Pack years 
29 (19.3) 
14.9 ± 11.7 
7 (29.2) 
15.9 ± 10.7 
22 (17.5) 
14.6 ± 12.2 
0.185 
0.621 
Family history of CVD 21 (14.0) 6 (25.0) 15 (11.9) 0.0911 
Haemoglobin 12.4 ± 1.4 12.1 ± 1.7 12.4 ± 1.2 0.416 
HbA1C 5.9 ± 1.1 6.3 ± 1.4 5.9 ± 1.0 0.193 
Total cholesterol, mmol/L 5.1 ± 1.9 4.8 ± 1.2 5.2 ± 1.2 0.199 
Triglycerides, mmol/L 1.4 ± 0.9 1.5 ± 0.8 1.4 ± 0.9 0.511 
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HDL, mmol/L 1.4 ± 0.4 1.4 ± 0.3 1.5 ± 0.4 0.186 
LDL, mmol/L 3.1 ± 1.1 3.1 ± 0.8 3.1 ± 1.2 0.717 
Menopause ** 
       Early menopause 











         - 
<0.0001 
Continuous variables presented as mean ± standard deviation, *applicable to 126 patients, 19 
in the presence CVD group and 107 in the absence of CVD group, **applicable to 134 
female patients, 19 in the presence of CVD group and 115 in the absence of CVD group,  
HbA1C=glycated haemoglobin, HDL=high density lipoprotein, LDL=low density lipoprotein 
 
Electrocardiogram and echocardiogram findings  
 
Only 123 patients of the total study group had an ECG performed within the previous 12 
months, of which, 88 (71.5%) were normal. Abnormalities present in the remaining 35 
(28.5%) ranged from sinus tachycardia 9 (7.3%), sequelae of ischaemic heart disease (IHD) 6 
(4.9%), left axis deviation (LAD) 6 (4.9%), features of right heart disease 5 (4.1%), left 
ventricular hypertrophy (LVH) 4 (3.3%), left bundle branch block (LBBB) 2 (1.6%), sinus 
bradycardia 2 (1.6%) and ventricular ectopics 1 (0.8%).   
 
Only 124 patients of the total study group had an echocardiogram performed, of which 
abnormalities were found in 74 (60%), with valvular heart disease the most common 58 
(47%), followed by features of IHD 11 (9%), cardiomyopathy 2 (2%), and the remaining 2% 
attributed to pulmonary hypertension, dextrocardia and pericardial disease one each 
respectively.   
 
In CVD-free RA patients, findings of 105 ECGs and 104 echocardiograms are shown (Figure 
















































Cardiovascular disease predictive risk assessment  
 
The four most common and validated CVD risk assessment models were applied to 126 
patients without CVD and the predicted 10 year risk was calculated (Figure 3).  
  
The risk estimates varied widely between models. Estimated high risk was 24.3%, 47.8%, 
34.7% and 5.2% for the Framingham, modified Framingham, QRisk3 and Reynolds CVD 
models. Estimated intermediate risk was 21.7%, 22.6%, 26.6% and 10.4% respectively. The 
comparison of different levels of risk between the various scoring models showed a similar 
distribution of high and intermediate risk observed between the Framingham and QRisk3 
score only (p = 0.07, p = 0.37), with similar distribution of low risk observed between the 
modified Framingham and QRisk3 score only (p = 0.1396).  
 
  




With the burden of CVD now shifting to low income or developing countries [22, 43-45], 
coupled with the well-established excess cardiovascular risk in RA [7], this study, albeit 
small, is one of few studies from sub-Saharan Africa to describe the relationship between RA 





















Frequency distribution of cardiovascular risk in scoring models 







The mean age and gender ratio of RA patients in the study were similar to global studies [4, 
46-49]. The majority of patients were Black and Indian ethnicity, reflecting the demography 
of KZN, which is in contrast to a study by Solomon et al. in Johannesburg, SA, where Blacks 
and Whites were the majority (46.5% and 36.6% respectively), and Indian and Coloured the 
minority ethnic  groups [22]. However, with the absence of a national registry, the true 
prevalence of RA in South African ethnic subpopulations is unknown, with unclear 
geographical and socio-demographic differences.  
  
The significantly older age in patients with CVD and long RA disease duration in this study 
is consistent with studies confirming that CVD prevalence is higher in older patients with 
established RA, and disease duration in excess of 10 years [5, 47]. Further, mortality trends in 
recent 15-year prospective cohort study, showed Dutch patients with RA had a 54% higher 
risk of mortality compared to the general Dutch population, however, in the last three years 
of study an equal mortality risk between the two groups was shown, a trend likely attributed 
to treatment intensification in the last decade [50].  
 
Contrary to findings from the multinational Questionnaires in Standard Monitoring of 
Patients with Rheumatoid Arthritis Program (QUEST-RA) study which showed a higher 
independent association of CVD event occurrence in men [5], our study showed a quadruple 
higher prevalence of CVD in women compared to men, however a higher relative risk of 
CVD observed in men. These findings could be attributed to the limited number of men in 
this study, and inferences are guarded.  
   
Indian patients, not unexpectedly, had a higher prevalence compared to both Black and White 
patients. These findings were consistent with a study by Enas et al. where a 1.5 to 4 fold 
increase in CVD mortality was observed in Indian migrants to SA compared to indigenous 
populations [51]. Findings from a door to door survey in India showed the prevalence of RA 
in India is similar to that reported in developed countries, and is higher than that reported in 
rural Africa [52].  
 
In contrast to the literature which shows seropositivity is associated with an excess risk in 
cardiovascular morbidity and a six fold increase risk of CVD mortality [4, 39, 53], no 
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difference was seen in seropositive or seronegative disease, however extra-articular disease 
was significantly associated with CVD, consistent with other study findings [5, 11].  
 
Overall, although no difference in functional status, disease activity or radiological 
involvement was observed between the subgroups, this may be due to small numbers and that 
both groups were receiving similar level of care. In contrast, CRP and ESR, which are 
associated with increased cardiovascular risk, and are independent prognostic markers of 
CVD mortality [4, 49, 54-57], were higher in the CVD group, although this did not reach 
statistical significance.  
 
Sulphasalazine use was associated with a higher likelihood of CVD, which is in contrast to a 
study which showed sulphasalazine was associated with significant lower CVD risk 
compared to patients who are DMARD naïve [58]. However, the majority of patients in this 
study were on one/multiple DMARDs and therefore the actual effect of DMARD use cannot 
be determined.  
  
The prevalence of hypertension in Africa ranges between 15 and 30% in adults [59], and is a 
common co-morbidity in RA [22, 60-62]. Congruent with this, more than half of our study 
population was treated for hypertension, with no statistical significance between subgroups. 
Further, a local study by Dessein et al. found a higher prevalence of uncontrolled 
hypertension among RA patients compared with the general population, with the employment 
of twice the number of antihypertensive agents in RA patients compared with non RA 
controls [62]. We did not examine anti-hypertensive medication in detail in this study.  
 
Dyslipidaemia similar to other studies was observed more frequently in the CVD group (3, 8, 
11), with lipid studies reflecting more favourable parameters, likely explained by the use of 
statin therapy as part of secondary CVD prophylaxis in this subgroup.  
 
In a recent meta-analysis of traditional cardiovascular risk factors in RA, an increased 
prevalence of DM was reported [63]. A local study in an RA population found an increased 
prevalence of DM in South African Black patients, compared to White, Asians and Mixed 
ancestry patients [16]. In this study, similarly a significant number of patients were on 
treatment for DM, with a significantly higher frequency in the CVD subgroup. Although an 
overall higher HbA1C was observed in patients with CVD, this did not reach statistical 
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significance (6.3 vs 5.9, p = 0.193), likely secondary to patients in the CVD subgroup being 
on targeted glucose lowering therapies.  
  
Physical inactivity is a common consequence of RA due to pain or extra-articular cardio-
pulmonary disease, with studies showing RA patients walked significantly less than non RA 
controls [64, 65]. Majority of patients in this study were sedentary, with similar physical 
activity in both groups, and consequently more than two thirds of the total group had an 
elevated BMI. This is in agreement with studies observing reduced lean muscle mass and 
increased body fat accumulation in RA, which translates to an increased metabolic risk [44, 
66, 67]. Of note, the extremes of obesity were more common in patients without CVD, while 
an overweight BMI was more common in patients with CVD. This disparity could be 
explained by more fervent lifestyle modification in the patient counselled on secondary CVD 
prophylaxis following the diagnoses of two life altering chronic diseases.  
  
This cluster of the above-mentioned classical cardiovascular risk factors constitutes the 
metabolic syndrome (MetS), which is associated with a higher CVD risk beyond that 
attributed by its individual components [68]. In a North African study by Rostom et al. the 
frequency of MetS was higher in RA compared to the general population [69]. In a local 
study, the prevalence of MetS in Black women with RA was as high as 30.8% [70]. Although 
not analysed in this study, the high prevalence of hypertension and obesity, would suggest an 
associated increased prevalence of MetS.   
 
Owing to the high prevalence of comorbid disease, and majority of patients in the study 
group using traditional NSAIDs, it isn’t surprising to find CKD as a common finding. A 
significant prevalence of CKD was observed in the CVD group, which is in agreement with a 
large scale study by Shlipak et al. describing CKD as an independent risk factor for 
cardiovascular morbidity [71].  
 
Majority of women in the study group were menopausal, and the increased risk of CVD in 
this group well established [72, 73]. Congruent to this, in our study CVD was more common 
in menopausal women. The differential cardiovascular effects of HRT are time dependent. 
Initiating HRT within 10 years of menopause onset is cardio-protective, with improvement in 
lipid profiles. Conversely, initiating HRT after 10 years post menopause or in the presence of 
established atherosclerosis has not shown a reduction in CVD events [72]. We found a higher 
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use of HRT in menopausal women in the CVD group; however these patient numbers were 
small. Despite the increased cardiovascular risk associated with premature menopause, no 
differences were observed in this study.  
Reported cardiac manifestations in RA are myriad, inclusive of CAD, heart failure, 
cardiomyopathy, pericarditis, cardiac amyloidosis, coronary vasculitis, dysrhythmia and 
valve disease [74]. Although pericarditis has been the most common reported abnormality 
[74, 75], majority of patients with established CVD in this study had CAD, followed by 
cardiomyopathy, valvular heart disease, dysrhythmia with low numbers of pericardial 
disease.  
Interestingly, in the subgroup without CVD, ECG abnormalities were present in 25% and 
echocardiogram abnormalities present in 58%, the majority of which was attributed to 
valvular heart disease, including mitral valve insufficiency, aortic valve insufficiency and 
tricuspid valve insufficiency, followed by features of IHD in 7.7%. This infers a high 
proportion of subclinical cardiac disease in RA patients, which is consistent to a small French 
study of echocardiogram findings in 30 RA patients free of known cardiac disease, 
demonstrating mitral valve insufficiency (80%), aortic valve insufficiency (33%), tricuspid 
valve insufficiency (23%), cardiomyopathy (37%) and pericarditis (13%) [48]. Despite a high 
prevalence of rheumatic heart disease in sub-Saharan Africa, none of the patients in this 
cohort gave a history of being diagnosed with rheumatic heart disease previously.  A 
prospective control study in this particular cohort of RA patients with subclinical cardiac 
disease would be of value, to ascertain if these cardiac lesions noted on echocardiogram 
manifest into clinical disease, as we cannot establish the aetiology currently in this cross 
sectional study. 
Further, in a large study of cardiovascular admissions and mortality in RA patients, between 
1981 and 2002, only 42% of patients who died from CVD had any previous admissions 
related to CVD during the study period, supporting the supposition of undiagnosed, 
subclinical disease [76]. Maradit-Kremers et al. observed that RA patients are less likely to 
report symptoms of angina, with unrecognised myocardial infarctions occurring more than 5 
times more frequently in RA patients and a doubling of the incidence of sudden cardiac death 
in RA patients compared with the general population [77]. A prospective study would 
determine whether our study findings of subclinical cardiac disease herald future CVD events 
necessitating intervention.   
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Current CVD risk assessment scores are poorly calibrated for patients with RA, with striking 
differences between observed and predicted CVD risk [14]. Similarly in this study, 
statistically significant disparity was observed between scores (p = <0.0001) at different 
levels of risk, with the exception of the Framingham and QRisk3 score which reported 
similar proportions of high and intermediate risk (p = 0.07, p = 0.37), and the modified 
Framingham and QRisk3 score with similar proportions of low risk (p = 0.1396). This raises 
concern, if a substantial proportion of patients with RA at high risk for CVD remaining 
unidentified depending on the score used.  Ultimately, the discriminant usefulness of risk 
scores in RA patients warrants further research with a prospective cohort design. 
  
The main limitation of this study is that the study was conducted in a single urban regional 
public hospital consisting mainly of Black and Indian patients and therefore findings may not 
be generalised across all ethnic or socio-economic groups. The number of males in the total 




The study confirms that the burden of traditional CVD risk factors in patients with RA are 
well established, with hypertension, DM, dyslipidaemia, physical inactivity and CKD of 
particular concern. Cardiovascular disease in RA was more common in women, older 
patients, and patients of Indian descent. The most common CVD found was CAD. Although 
no significant association was observed between RA disease activity or serological status; 
extra-articular disease was a common finding in RA patients with CVD.  
Cardiovascular disease risk management in RA should comprise of appropriate treatment of 
traditional risk factors as well as tight RA disease activity control. A comprehensive, 
discriminant CVD risk score is needed to appropriately risk stratify patients with RA, which 
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EXECUTIVE SUMMARY  
 
Rheumatoid arthritis (RA) is a chronic disease which affects both quality of life and life expectancy.  
The lifespan of a patient with RA is shortened by an average of a decade primarily due to the 
associated complications of premature cardiovascular disease.  A fundamental principle linking RA to 
cardiovascular disease is inflammation. A combination of both traditional and non traditional factors 
increase the adverse cardiovascular risk profile in patients with RA.   
 
Studies from developed countries show a higher risk of adverse cardiovascular events in patients 
with RA compared to the general population, with RA disease activity a predictor of cardiovascular 
disease. There is a paucity of studies in sub-Saharan Africa reflecting cardiovascular disease and risk 
profiles in patients with rheumatoid arthritis.  
 
In a resource constrained healthcare system, adopting preventative medicine in everyday practice 
translates into a far reaching impact on improving functional disability, economic, morbidity and 
mortality burden. This study expects to improve our knowledge of the cardiovascular burden in RA, 
and the study results will assist in developing risk assessment and health care targets for this specific 
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Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease, characterized by 
a symmetrical, peripheral polyarthritis [1]. The peak age of onset is between 30 and 50 years, and 
the disease has a predilection for women compared to men. It is considered as one of the most 
common inflammatory arthritis, with a natural history resulting in joint destruction, functional 
impairment and increased mortality [2]. In addition to the articular disease, extra-articular multi-
organ manifestations are seen in approximately 50 percent of all patients with RA at some point 
during the course of disease [1].  
 
The mortality rate amongst RA patients is increased by 70 percent compared to the general 
population [3], and the leading cause of death in RA is cardiovascular disease [3, 4]. Both traditional 
and non- traditional factors combine to increase the adverse cardiovascular (CV) risk profile in 
patients with RA, with CV deaths occurring five to ten years prematurely compared to the general 




The exact immuno-pathogenesis of RA is unknown [5], but it is postulated to involve genetic and 
environmental factors, with a complex interaction between T cells, B cells, and pro-inflammatory 
cytokines (Figure 1). The cytokines act as messengers that activate effector cells that cause the local 
and systemic symptoms associated with this disease [6]. 
 
The earliest detectable preclinical stage is the breakdown of self-tolerance. In the rheumatoid joint, 
resulting in activation of T cells that stimulate macrophages and synoviocytes to generate pro-
inflammatory mediators which eventually destroy cartilage and bone. The synovium becomes 
hyperplastic, and the synovial membrane expands. The destructive osteoclast rich portion of the 
synovial membrane is termed pannus [6]. T cells help B cells produce antibodies that promote joint 
inflammation. 
 
Activated B cells form plasma cells, which produce rheumatoid factor (RF) and anti-cyclic 
citrullinated peptide (CCP) antibodies [7]. Rheumatoid factor contributes to the pathogenic process 
by forming large immune complexes inside the joint, fixing complement and promoting 
chemoattractant [7]. In contrast, anti-CCP antibodies are directed against deiminated peptides and 
they recognise citrulline containing matrix proteins, which enhance the expression of self-reactivity 
[7].  
 
The pro-inflammatory cytokine; tumour necrosis factor-alpha (TNF-α), plays a critical role in the 
pathogenesis of RA [8]. Tumour necrosis factor-alpha together with interleukin (IL) 1, 6 and 17, 
increases the expression of receptor activator of nuclear factor kappa ligand (RANKL) which 
stimulates osteoclast differentiation and bone resorption in the joint, thus promoting 
osteoclastogenesis.  Simultaneously TNF- α also inhibits osteoblast differentiation, thereby actively 
suppressing new bone formation. Additionally IL 6, IL 1 and TNF-α together promote the synthesis of C reactive 
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protein (CRP) in hepatocytes. In addition to eliminating infection, CRP plays a regulatory role in inflammation and atherosclerotic 
thrombosis [3, 9]. Since CRP is a direct measure of synovial inflammation and a by-product of inflammatory reactions in RA, and therefore 
it is a useful marker of disease activity [3, 9]. Emerging evidence supports the role of CRP as a  pro-inflammatory bone destructive molecule 
in the pathogenesis of RA [9].   
 
Persistently elevated C-RP levels exacerbate tissue damage, promote lipid-metabolism dysregulation 
and increases the risk of cardiovascular complications [6]. The combined effects of TNF-α, IL-6, acute 
phase reactants, immune complexes, and pro inflammatory high density lipoprotein (HDL) 
phenotype, increase endothelial activation and render atheromatous plaques unstable. Cytokine 
driven insulin resistance of muscle and adipose tissue results in an “inflammatory metabolic” 
syndrome [10].  
 
Risk factors for rheumatoid arthritis 
 
Several factors influence the development, rate of progression and severity of RA (Figure 1). 
Although several genetic loci have been described, greater than 80% of patients with RA carry the 
epitope of the human leucocyte antigen (HLA)-DRB1*04 cluster [11]. Patients expressing the HLA-
DRB1*04 cluster inherit a higher risk for nodular disease, major organ involvement and surgery 
related joint destruction [6]. Further strengthening the genetic theory are twin studies that show a 
concordance rates of 15 to 30% among monozygotic twins and 5% among dizygotic twins [10]. 
 
Gene-environment interactions underlie the association of different genotypes in different 
geographical and cultural settings [4]. Locally, an urban-rural regional variation of disease, with a 
higher prevalence in the South African urban population compared to virtually no cases reported in 
some rural areas is observed [12]. Further, studies also suggest a role for occupational factors, such 
as exposure to dust, asphalt and silica, causing bronchial stress and thereby increasing  the risk for 
anti-CCP antibody positive RA [10]. 
 
Cigarette smoking, particularly in seropositive and extra-articular RA is a strong associative factor [4]. 
Both the smoking intensity and duration increase the risk and additionally citrullination of proteins in 
broncho-alveolar fluid occurs more often in smokers. The long-term tobacco smoke exposure and 
citrullination of proteins induce self-reactivity resulting in anti-CCP positive disease, which confers a 
less favourable prognosis than anti-CCP negative disease [10].   
 
Although there is no clear role for a hormonal influence, it is felt that oestrogen stimulates TNF-α 
resulting in an increased risk in women. Further women usually have poorer outcomes than men [4, 
10]. Similarly there is conflicting data on lifestyle and education level, and disease occurrence. Whilst 
several studies found a higher prevalence in highly educated, high-income classes, compared with 
uneducated, lower-income classes others show conflicting results [4]. 
 
Infectious agents are increasingly being implicated in the aetiology of RA, on a postulated 
background of molecular mimicry. The formation of immune complexes during an infection triggers 
the induction of RF. Possible infectious triggers include Epstein-Barr virus, cytomegalovirus, 
parvovirus, proteus species, escherichia coli and mycoplasma [4, 10]. Studies involving clinical 






Figure 1. Postulated factors associated with the development of rheumatoid arthritis [10] 
 
Epidemiology   
 
Rheumatoid arthritis is not a recent disease and descriptions of symmetric, chronic polyarthritis with 
characteristic deformities were described in Rome in 100 BC and India in 500 BC [13]. 
 
The epidemiology of RA is well described in developed countries, with estimates from Western 
Europe and North America reporting a global prevalence of between 0.3% and 1% [14]. In contrast, 
RA is thought to have a lower prevalence, with a milder disease course in developing countries. 
 
The Global Burden of Disease 2010 study, conducted in 187 countries, based on the 1987 American 
College of Rheumatology (ACR) classification criteria for RA, found the global prevalence of RA was 
0.24% , however the true global prevalence of RA remains unknown [14]. The study used the 
outdated 1987 ACR classification criteria for RA, which fails to recognize early RA, and hence 
employment of these classification criteria in this study ignored the mathematical weight of such 
patients. Further, since prevalence data was not available for multiple regions, Sub-Saharan Africa 
included, data was then modelled using a meta-regression tool [14]. This could significantly 
attenuate the actual burden of disease in African countries, and therefore the true global prevalence 




There is a paucity of prevalence data for RA from Africa and a recent systematic review showed an 
overall prevalence which ranged from 0.13% in Algeria to 2.54% in South Africa (SA) [15]. Variations 
in urbanisation, cultural and geographical diversity amongst countries contributed to significant 
statistical heterogeneity in the overall meta-analysis [12].   
 
Similar to the rest of Africa, local data for prevalence of RA in SA are lacking and environmental 
factors, urban-rural gradient, contribute to the differences seen in various South African populations 
[16]. The highest prevalence of 0.9% is found in a mixed urban community in Soweto, followed by 
the Xhosa of Transkei with 0.68%, the Sotho’s of Lesotho with 0.3%, and the Tswana of Western 
Transvaal with 0.1% [16].  
 
Clinical expression of disease  
 
The articular expression of disease includes mono-articular, oligo-articular or poly-articular 
symmetrical synovitis, with early morning stiffness lasting more than one hour [7].   Both small and 
large joints are affected, with untreated disease progressing to joint deformities. 
 
Extra- articular disease is found in almost 50% of patients with RA at some point during the course of 
disease [1]. Patients with RA at risk for extra-articular disease include smokers, early onset disability 
and RF or anti-CCP antibody seropositive disease. The most frequent manifestations include 
subcutaneous nodules, secondary Sjogren’s syndrome, pulmonary nodules and a normochromic, 
normocytic anaemia [7]. Other manifestations include osteoporosis, scleritis, episcleritis, vasculitis, 
pulmonary features of pleural effusions, interstitial lung disease, idiopathic pulmonary fibrosis, 
pulmonary nodules pulmonary hypertension, haematological features of thrombocytopaenia, 
leucopaenia, neurological features of mononeuritis multiplex, peripheral neuropathy, nerve 
entrapment, and cardiovascular features of cardiomyopathy, pericarditis, valvular heart disease, 
coronary artery disease and atherosclerosis [7].  
 
Diagnostic criteria for rheumatoid arthritis  
 
Prior to 2010, the 1987 ACR classification criteria for RA (Table 1) were used. The criteria looked at 
seven domains including symmetrical small joint involvement, early morning stiffness, radiological 


















Abbreviations : MCP, metacarpophalangeal; PIP proximal interphalangeal 
  
The above criteria was criticised for the lack of sensitivity for early disease, which lead to the 2010 
ACR/ European League Against Rheumatism (ACR/EULAR) RA Classification Criteria (Table 2) , which 
are currently in use. The revised criteria recognised are more inclusive, with the addition of 
inflammatory markers, and anti-CCP sero-positivity, allowing for earlier diagnosis and treatment 















TABLE 2. The 2010 American College of Rheumatology/European League Against Rheumatism  
classification criteria for RA [19]  
 
 
Large joints refer to shoulders, elbows, hips, knees and ankles 
Small joints refer to metacarpophalangeal joints, proximal 
interphalangeal joints, second through to fifth metatarsophalangeal 
joints, thumb interphalangeal joints and wrists 
Low positive values refer to values less than three times the upper limit of normal 
High positive values refer to values greater than three times the upper limit of normal 
ACPA, anti-citrullinated protein antibody; ESR, erythrocyte sedimentation rate 
 
Disease activity  
 
Disease severity is a predictor of mortality [4], with premature mortality from cardiovascular disease 
related to the number of inflamed joints [20], and persistently elevated inflammatory markers [3].  
There are several disease activity scores that are used [2, 21]. A composite disease activity score is 
obtained by using a combination of clinical examination of tender and swollen joints, global 
assessments and laboratory investigations [21]. The ACR core set for disease activity includes the 
following [2]: 
 
 Tender joint count 
 Swollen joint count 
 Patient pain assessment 
 Patient global assessment 
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 Doctor global assessment 
 Function  
 Acute phase reactant 
 Radiographic analysis 
 
The twenty eight joint count is most widely used. Function and pain is assessed in a patient-centred 
health assessment questionnaire (HAQ). The HAQ provides fundamental knowledge about a 
patient’s health, functional status, satisfaction and quality of life from their own personal 
perspective [22]. The HAQ has been validated in multiple studies, such as prediction of successful 
aging, inversion of the therapeutic pyramid in RA, and examination of mortality risks in RA, work 
capacity and performance, occupation and the ability to live independently [22].  
 
Composite scores provide a more accurate reflection of overall state of disease compared to 
individual measurements. The most widely used composite scores in current practice are the Disease 
Activity Score (DAS) 28, involving tender and swollen 28 joint count together with acute phase 
reactants and patient global assessment [2]. The Simplified Disease Activity Index (SDAI) combines 
the sum of tender and swollen 28 joint count, patient and doctor global assessment and acute phase 
reactants and lastly the Clinical Disease Activity Index (CDAI) which is a modification of the SDAI 
without inclusion of acute phase reactants [2]. Acute phase reactants measured include the CRP or 
erythrocyte sedimentation rate (ESR).  
 
The score further defines disease activity into remission, low, moderate or high disease activity 
(Table 3).  
 








The incidence of cardiovascular events in patients with RA occurs three times more frequently than 
in the general population [6]. Accelerated coronary artery atherosclerosis is associated with 
increased mortality in RA [23]. This excess mortality is more pronounced in studies of RA populations 
with longer disease duration than in cohorts with early arthritis [24]. The global Questionnaires in 
Standard Monitoring of Patients with Rheumatoid Arthritis Program (QUEST-RA) study, with a cohort 
of 4363 patients, conducted in 2005-2006, found an overall prevalence of cardiovascular morbidity 
of 9.3%. There was considerable variation between countries, with the highest prevalence in the 
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United States of America (USA), United Kingdom, Poland and Germany, and the lowest in Argentina 
and Mediterranean countries [23]. These findings were similar to in the World Health Organisation 
(WHO) multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) 
project [25], which found an overall prevalence of lifetime myocardial infarction of 3.2%, and stroke 
of 1.9% [23]. Further cardiovascular events were more prevalent in men than women and occurred 
approximately a decade earlier in patients with RA, than the general population, suggesting that RA 
is an independent risk factor for premature ischaemic heart disease [23]. 
 
Prevalence of traditional cardiovascular risk factors extrapolated from the QUEST-RA study, were 
hypertension (33%), dyslipidaemia (14%) for, diabetes mellitus (8%), smoking (43%), physical 
inactivity(72%), and obesity (18%) with diabetes and smoking both being more common in men than 
women. Additionally extra-articular disease was significantly associated with cardiovascular 
morbidity [23].  
 
Rheumatoid arthritis increases the lifetime risk for coronary artery disease (CAD) two fold compared 
to the general population and this risk is of equal magnitude to patients with diabetes mellitus [26, 
27]. The increased risk of heart disease in patients with RA is reflected in modification of the 
Framingham cardiovascular risk score, which requires a multiplication factor of 1.5 in patients with 
RA. Further patients with RA have a two-fold increased risk of developing heart failure. Seropositive 
disease is associated with diastolic dysfunction, with a preserved ejection fraction of more than 50% 
[26]. The outcome of patients with RA and heart failure is poorer than the general population [26].  
 
Further, a small study found an increased frequency of asymptomatic cardiac involvement in RA 
patients [28]. Based on echocardiographic findings 37% had cardiomyopathy, 7% residual 
abnormalities of a myocardial infarction, 83% valvular heart disease with mitral regurgitation being 
the dominant lesion, and 13% had pericarditis. Electrocardiogram abnormalities were found in 63% 
of patients, which included left ventricular hypertrophy, sequelae of myocardial ischemia, first-
degree atrioventricular block, right bundle branch block and right atrial hypertrophy [28].  
 
Traditional cardiovascular risk factor profile in rheumatoid arthritis  
 
1. Dyslipidaemia  
In RA, traditional cardiovascular risk factors are influenced by both inflammation inherent to the 
disease, and pharmacodynamics of anti-rheumatic drugs. Cholesterol, particularly low density 
lipoprotein (LDL), forms fatty streaks in coronary arteries, which foster flow-limiting atherosclerotic 
plaques [29]. When these plaques rupture, thrombosis ensues, leading to blockage of coronary 
arteries and myocardial infarction. Rheumatoid arthritis related dyslipidaemia is characterised by 
low total cholesterol and HDL, and elevated triglyceride and small LDL [3]. During periods of high 
grade inflammation, there is marked suppression of total cholesterol, HDL and LDL levels, yielding an 
unfavourable pro-atherogenic ratio of total cholesterol to HDL [26].  
 
The total cholesterol to HDL ratio is a better cardiovascular disease risk predictor in RA than 
individual lipid components [27] and studies show HDL levels are significantly lower in RA patients 
compared to matched control subjects [30]. This paradoxical relationship between inflammation and 
lipid profiles translates into increased CAD risk in RA. Inflammation in RA alters lipoprotein structure 
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and function and the HDL load of serum amyloid A increases with a decrease in apolipoprotein A-I, 
leading to a shift in the anti-atherogenic effect of HDL to a pro-atherogenic effect [26].  
 
Further the anti-inflammatory effects of drugs on lipid profiles are inconsistent. While there is 
evidence that hydroxychloroquine improves atherogenic lipid profiles [31], the role of methotrexate 
the gold standard of treatment is unclear. Tumour necrosis factor (TNF) α blockers elevate both total 
cholesterol and HDL levels, resulting in a stable atherogenic profile [29] while tocilizumab, an IL-6 
inhibitor, elevates total cholesterol and LDL [29].  
 
2. Insulin resistance and diabetes mellitus  
Cytokine driven mechanisms make muscle and adipose tissue insulin resistant, resulting in an 
“inflammatory metabolic” syndrome [10]. Epidemiological data supports a strong association 
between RA and insulin resistance, and a study showed that 54% of patients with RA compared to 
40% in the general population had insulin resistance [32]. Further significantly higher insulin 
resistance was seen amongst patients with high-grade inflammation. Predictors of insulin resistance 
included elevated CRP, ESR, IL-6, TNF-α and increased waist circumference [29]. Additionally studies 
show a positive association between RA and diabetes mellitus, and a 50% increase in the risk of 
diabetes mellitus in RA, even after controlling for glucocorticoid use [33]. In contrast, studies on drug 
effects on insulin resistance, have found a decrease in insulin resistance with common disease 
modifying drugs including methotrexate, TNF-α blocker and hydroxychloroquine use [29].  
 
3. Hypertension  
Although several older studies found no difference in hypertension between RA and control groups 
[29], studies that are more recent show that hypertension is often underdiagnosed and 
undertreated in patients with RA [26]. Inflammation and drug effects of non-steroidal anti-
inflammatories (NSAID) and glucocorticoids [26, 29] may exacerbate hypertension in RA. Further 
studies on arterial wall pliability; have found increased arterial wall stiffness in patients with RA, 
suggesting a diminished ability of the arterial system to respond to changes in blood volume [29]. 
 
4. Obesity 
Obesity is defined as a body mass index (BMI) of greater than 29 kg/m2 by the WHO. In the non RA 
population, obesity is associated with higher CRP, which is associated with an increased 
cardiovascular risk [34]. The prevalence of obesity is 54% higher in patients with RA than non RA 
control groups [29] and a combination of low muscle mass and high fat mass is observed in RA [26].  
 
Further visceral adiposity in RA is associated with hypertension, insulin resistance, metabolic 
syndrome and a greater inflammatory load [26].  Studies also show men with RA have higher levels 
of visceral fat compared to controls, whilst women with RA had increased subcutaneous fat 
compared to controls with a similar BMI and waist circumference [29]. Lastly adipose tissue releases 
pro-inflammatory cytokines, IL-6 and adiponectin, thus contributing to low grade inflammation. 
Therefore, obesity in RA is associated with higher CRP levels and aggressive articular disease [29].  
 
5. Physical inactivity  
Physical activity is an important modifiable risk factor of cardiovascular disease. Studies show that 
patients with RA are significantly less physically active than population based controls. A 
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combination of uncontrolled inflammation, low muscle mass, increased body fat composition, and 
limitations of joint movement from poor disease control, contributes to lack of exercise. This 
physical inactivity, as in the general population, leads to hypertension and dyslipidaemia, which 
portends an unfavourable cardiovascular profile [29].  
 
6. Cigarette smoking  
Cigarette smoking is one of the most prominent modifiable risk factors for cardiovascular disease. It 
is also the strongest known environmental risk factor for RA [29]. Smoking is associated with multi-
vessel coronary artery calcification [35]. Recent case controlled studies highlight a higher prevalence 
of current or past cigarette smoking observed in patients with RA [29]. The Multiple Risk Factor 
Intervention Trial (MRFIT) found twice the number of coronary heart disease deaths in the smokers 
compared to the non smokers. Additionally the study found a strong association between CRP and 
subsequent risk of cardiovascular deaths among cigarette smokers that is independent of the 
number of cigarettes smoked per day [36].  
 
Rheumatoid arthritis as an independent risk factor for cardiovascular disease   
 
There is mounting evidence that the increased cardiovascular morbidity and mortality in RA is due to 
the pro-atherogenic changes seen with systemic inflammation rather than it being due to traditional 
cardiovascular risk factors only (Figure 2) [37, 38].This has resulted in the recognition of RA as an 
independent cardiovascular risk factor [23, 39].  
 
Studies in the Pima Indians of Arizona, USA who have the highest prevalence of RA in the world 
found the presence of swollen, tender joints was a predictor of cardiovascular mortality 
independent of traditional cardiovascular risk factors [40]. Further studies show that HLA-DRB1, 
promotes survival of autoreactive T cells, which mediate chronic inflammation [26]. These T- cells 
also play a role in atherosclerotic plaque formation by producing cytokines and damaging vascular 
smooth muscle cells [26]. The HLA-DRB1 gene is associated with an increased risk of myocardial 
infarction and other non-RA associated heart disease [41, 42]. Supporting evidence of their effects 
has been shown in the use of T cell inhibiting drugs currently used in percutaneous drug eluting 
stents in CAD, thereby preventing in-stent stenosis [26]. 
 
The rheumatoid joint synovial tissue releases in abundance TNF-α, IL-6 and IL-1, which alters the 
function of adipose tissue and vascular endothelium [3]. These changes produce dysregulation in 
glycaemic control, lipid profiles and endothelial function [3]. The Physicians Health Study in the 
general population found higher IL-6 levels in men who experienced their first myocardial infarction 
compared to those who remained cardiovascular disease free during a six year follow up [43]. This 
highlights the atherogenic role of IL-6 in RA [6]. 
 
Carotid artery intima thickness, which has been used as a marker of early atherosclerosis, is 
increased in patients with RA. This correlates with markers of systemic inflammation in patients with 
RA [44]. Shared mechanisms of immunological disease, systemic endothelial activation and 
circulating immune complexes lead to increased pro-thrombotic markers and increased arterial 
stiffness in RA [45]. The prevalence and severity of coronary calcification is increased in patients with 




Studies show a positive relationship between cardiovascular biomarkers and active RA [46]. Bony 
erosion, a sequelae of persistent inflammation, occurs in 80% of patients untreated or inadequately 
treated within one year following diagnosis [10] predicts cardiovascular events and mortality in RA 
[24]. Further the QUEST-RA study supports the association of higher cardiovascular morbidity with 
severe RA [23]. Recent evidence suggests cardiovascular risk for patients with RA in remission is 
similar to non RA controls [47]. Cardiovascular risk increases by 7% for each additional RA acute flare 
[47]. This highlights the concept of accumulating cardiovascular damage with each acute flare, and 
possibly explains the excess cardiovascular risk in RA patients compared to non RA controls.   
 
Seropositive disease confers an excess risk in cardiovascular morbidity and mortality [27] and anti 
CCP antibodies are independently associated with the development of ischaemic heart disease [48].  




Figure 2. Determinants of heart disease in patients with rheumatoid arthritis  
compared to the general population [26] 
 
Role of pharmaco-therapeutics in rheumatoid arthritis and effects on cardiovascular risk  
 
Disease modifying anti-rheumatic drugs (DMARD) that target joint inflammation also decrease 
arthrosclerosis risk and have proven beneficial effects on RA associated cardiovascular disease [24].  
 
Methotrexate, an anchor drug in RA treatment, is associated with a 21% reduction in cardiovascular 
events [26]. In a small study of 22 patients with RA, 14 patients who commenced methotrexate had 
a decrease in insulin resistance during the first eight weeks [49]. Tumour necrosis factor-α inhibitor 
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therapy is associated with reduced risk of all heart disease events [26], further this class of drugs 
favourably affect HDL lipid profiles [50]. In addition, it improves endothelial function and insulin 
resistance [26].  
 
Hydroxychloroquine also improves lipid profiles, with a reduction in LDL, and total cholesterol/HDL 
ratio, and decreases the risk of diabetes mellitus in patients with RA [26].  
 
There is conflicting data on the use of glucocorticoids. Older studies showed that steroid use 
resulted in hypertension, decreased insulin sensitivity, elevated lipid levels, and increased carotid 
plaque and arterial stiffness [51]. Patients who are treated with prednisone doses greater than 7.5 
mg per day appear to have twice the risk of heart disease compared to those who did not receive 
steroids [52]. However, recent findings from the QUEST-RA study show that the fundamental effects 
of lowering inflammatory burden, correlates with an independent association of long-term 
glucocorticoid use and a reduced risk of all cause cardiovascular events [23]. Further, the benefit of 
reducing high-grade inflammation in an acute flare may counteract the adverse cardiovascular 
effects of glucocorticoid use [27].  
 
Both selective and non-selective NSAIDs are known to cause clinically significant hypertension, which 
may require treatment [53]. The use of NSAID’s and its association with cardiovascular risk was 
brought to the fore in the Vioxx Gastrointestinal Outcomes Research (VIGOR) study. An increased 
risk of heart disease was found with rofecoxib use [54]. A meta- analysis has shown no differences in 
heart disease events with celecoxib or ibuprofen use, and naproxen conferred the lowest 
cardiovascular risk [55].  
 
Cardiovascular risk assessment in rheumatoid arthritis  
 
There are several validated cardiovascular risk assessment tools available for use including the 
Framingham Risk Score (FRS), and the Systematic Coronary Risk Evaluation Score (SCORE), which 
determines the 10-year risk of fatal cardiovascular disease (Table 4). Additionally, tools like the 
Reynolds Risk Score (RRS) takes into account traditional risk factors as well as the added risk of 
inflammation, in identifying the 10-year risk for a myocardial infarction (MI) or stroke. Studies have 
illustrated that traditional risk factors account for only a portion of the overall risk for cardiovascular 
disease in RA, with the additional risk attributed to inflammation [37, 38]. Therefore the lack of 
recognition of inflammatory markers in FRS and SCORE, underestimates the cardiovascular risk in 
RA. An expert panel convened by EULAR, recommends a multiplier of 1.5 for FRS and SCORE if a 
patient fulfils two or more of the following: RA disease duration more than 10 years, RF or ACCP 










TABLE 4. Comparison of clinical variables and risk outcomes in the Framingham Risk Score, Reynolds 
Risk Score and Systematic Coronary Risk Evaluation Score [29] 
  
 




A fundamental principle linking RA to cardiovascular disease is the shared inflammation. Further 
studies suggest that patients with RA are less likely to receive primary or secondary heart disease 
preventions [26]. Therefore understanding the cardiovascular risk in a patient with RA, requires a 
revolutionary conceptual model that highlights the overlapping influence of traditional risk factors 
and inflammation.  
 
From the 2014 World Health Organisation (WHO) statistical profile, life expectancy in South Africa 
has increased, with life expectancy at birth to be 59 years. With aging populations, the number of 
people living with RA will increase substantially in the forthcoming decades [56]. 
 
Cardiovascular risk management in patients with RA requires an evaluation of biomarkers, control of 
traditional risk factors, and good RA disease control. Early control of disease activity in RA predicts 
significant survival benefits. A robust preventative strategy of cardiovascular disease in this high-risk 
group is required. The study intends to improve our knowledge of RA and cardiovascular profile in 
our setting, and study results can be applied to developing a framework for risk assessment and 

















To describe the cardiovascular profile of patients with rheumatoid arthritis in a regional arthritis 
clinic. 
 
Objectives   
1. To determine the prevalence of cardiovascular disease in rheumatoid arthritis. 
2. To describe the prevalence of traditional cardiovascular risk factors in RA.  





This is a retrospective, descriptive chart review of patents with rheumatoid arthritis currently 
attending the rheumatology clinic at King Edward hospital. The disease activity and cardiovascular 
risk profile will be reviewed.    
 
Setting: 
The study will be conducted at King Edward VIII Hospital, a tertiary care centre in Kwa-Zulu Natal 
(KZN) Kwa-Zulu Natal is found on the south east coast of South Africa (SA) and is the second most 
populous South African province, with a population of 10.27 million people, comprising 20% of the 
total population of SA [57], of which 86.8% is Black African and 7.4% is Indian [58].  
 
King Edward VIII Hospital, opened in 1936, is the second largest hospital in the southern hemisphere. 
It is a 922 bedded hospital with 360 000 outpatients. It offers a regional and tertiary public 
healthcare service to Kwa-Zulu Natal. It is an academic teaching hospital linked to the University of 
Kwa-Zulu Natal Nelson R. Mandela School of Medicine [59]. The hospital’s arthritis clinic is a 
dedicated weekly run rheumatological service, under the stewardship of a team comprising a 
rheumatologist, general physicians and medical officers.  
 
Study population:  
The files of all current patients diagnosed with RA as per  1987 American College of Rheumatology 
classification criteria or 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria,  seen in the last six months at King Edward VIII Hospital arthritis 
clinic will be included. 
  
Inclusion criteria: 
 Patients diagnosed with rheumatoid arthritis fulfil : 
1. 1987 American College of Rheumatology classification criteria for rheumatoid 
arthritis, if clinical presentation prior to 2010 
and/or 
2. 2010 American College of Rheumatology/ European League Against Rheumatism 
Collaborative Initiative classification criteria for rheumatoid arthritis, if clinical 
presentation after 2010  





 Patients younger than 18 years   




This study is a retrospective chart review of all patients attending the arthritis clinic at King Edward 
VIII Hospital, which includes approximately 120 subjects. All patients are usually reviewed on a two 
to four monthly basis. As such, over a six month period, every chart will be reviewed.  
   
The following statistical parameters were used to determine an appropriate sample size with a 
statistical power of 80%. In this binary logistical model, the probability of the presence of CV disease 
is estimated given a number of independent/predictor risk factors. This means there are two 
outcomes of this model: presence of cardiovascular disease and absence of cardiovascular disease.  
 
The following statistical parameters were used to arrive at a sample size. 
1. Type 1 error (α) = 0.05 (the probability of falsely rejecting null hypothesis) 
2. Type 2 error (β) = 0.2 (the probability of falsely accepting null hypothesis)  
 
The assumption is the sample is a good representation of the population from which it came from, 
with a standard deviation (ơ) of 1 and population mean (µ) of 0 (Gaussinal or normal distribution). 
On the basis of the above, a sample size of 113 was determined. NB. 113 +- 15% padding.  
 
Data Collection:  
The following data will be collected from the chart using a structured questionnaire.  
- Demographics will include the following: 
1. Age  
2. Gender 
3. Ethnicity  
4. Occupation 
5. Educational level  
6. Area of residence  
 
- Rheumatoid arthritis disease profile  
1. Date of diagnosis 
2. Presence of early morning stiffness and duration 
3. HAQ score (see appendix I)   
4. SDAI (see appendix II ) 
5. Serology  (Rheumatoid factor and anti-cyclic citrullinated peptide antibody)  
6. Presence of extra-articular features of rheumatoid arthritis  
7. Inflammatory markers at diagnosis and currently  (CRP and ESR) 
8. Radiological findings  
9. Dose and duration of drug therapy  
 
- Cardiovascular risk factors : 
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1. Co morbidities (Diabetes mellitus, hypertension, dyslipidaemia, cerebrovascular 
accident) 
2. Family history of cardiovascular disease and CV risk factors   
3. Ambulant arm blood pressure 
4. Anthropometry: last recorded  
 Weight 
 Height  
 BMI : According to WHO Classification  
- Obese class I : 30 to 34.99 kg/m2 
- Obese class II : 35 to 39.99 kg/m2 
- Obese class III : greater than 39.99 kg/m2 
5. Self reporting of smoking history, stipulated by pack years 
  6.    Self reporting of lifestyle habits including exercise per week  
7. If female, menopausal status  
- Electrocardiogram findings  
- Echocardiogram findings  
- Laboratory investigations (Haemoglobin, estimated glomerular filtration rate, glycated 
haemoglobin, lipid profile, thyroid function)  
 
Data Management:  
The ethical integrity of the study will remain within the domains of the strictest confidence held 
within the sanctum of a doctor/patient relationship. Access to this information will be limited to the 
principal investigator, the supervisor and the assisting statistician.  
 
Each patient meeting the inclusion criteria will be allocated a study number, to avoid duplication of 
patients and measurement error. Data will be entered onto a password protected Excel spreadsheet 
by the principal investigator and only de-identified data will be analysed. Data will be cross checked, 
validated and captured from source by the principal investigator, to assure reliability of data.  
 
Data analysis: 
Descriptive statistics will be used to describe the population frequency and percent to describe 
categorical variables.  Continuous variables will be summarised as mean ± standard deviation; 
medians and interquartile ranges (IQR) for variables that are highly skewed. Categorical variables will 
be summarised using proportions and percentages. Proportions and categorical variables will be 
compared using Pearsons Chi Squared test or Fishers exact test as appropriate.  
 
Binary logistical regression model will be used to identify independent variables that can predict the 
likelihood of a patient with RA having cardiovascular disease. The level of significance will be set at 
p<0.05.  
All statistical analysis will be conducted using SPSS version 24 (IBM Corp. Released 2016. IBM SPSS 
Statistics for Windows, version 24.0. Amonk, NY:IBM Corp.) and SAS version 9.4 (SAS version 9.4, 




The two groups (RA patients with and without CVS disease) will be compared using the student t-




A research protocol will be submitted to the University of KwaZulu-Natal Biomedical Research Ethics 
Committee (BREC) for ethical approval. Permission to conduct the research will be obtained from 
the medical manager of the hospital concerned after provisional BREC approval. Provincial approval 
will then be obtained before the study commences. Patient confidentiality will be protected and 
anonymity ensured by assigning a study number to each patient and by recording patient data on 
coded data sheets which do not contain patient identifiers. The study holds minimal risk to any 
patients as there is no intervention. 
 
Social value: 
Cardiovascular disease occurs prematurely in patients with rheumatoid arthritis. The knowledge in 
this study will allow us to gain a South African perspective on the cardiovascular disease risk profile 
among patients with rheumatoid arthritis. In a resource constrained healthcare system, adopting 
preventative medicine in our everyday practice translates into far reaching cost-cutting economical 
gains.  This study will serve as a foundation for understanding predictive risk and shaping future 
improved healthcare targets.  This study hopes to serve the ultimate goal of promoting a healthier 
nation living with a chronic disease with better quality of adjusted life years. 
 
Scientific validity: 
Fair selection of participants: 
Participants included in this study are adult outpatients to the arthritis clinic. They are selected 
according to the relevance to the research question. The patient selection process will be exercised 
strictly within the inclusion and exclusion criteria outlined.   
 
Assessment tools : 
The HAQ provides fundamental knowledge about a patient’s health, functional status, satisfaction 
and quality of life from their own personal perspective [22]. The HAQ has been validated in multiple 
studies, such as prediction of successful aging, inversion of the therapeutic pyramid in RA, and 
examination of mortality risks in RA, work capacity and performance, occupation and the ability to 
live independently [22]. The SDAI has been validated in multiple studies globally, particularly in their 
relationship to radiographic progression, functional decline and mortality risk [2].   
 
Risk/benefit balance: 
Data obtained from patients medical records will be handled in the strictest confidence by 
minimizing the number of people who analyse the data, having all data recorded on password 
protected documents, and all data recorded will have identifiers removed and replaced with a study 
number.  Patient’s anonymity is protected.   
 
Independent ethics review: 
A research protocol will be submitted to the University of Kwa-Zulu Natal Biomedical Research Ethics 
Committee for ethical approval. After obtaining provisional ethics approval, permission to conduct 
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research will be sought from the medical manager of King Edward VIII Hospital and provincial 
approval will be sought from the Kwa-Zulu Natal Department of Health.  
Patient recruitment will not commence until written ethics approval has been received from the 
University of Kwa-Zulu Natal registered research ethics committee.  
 
Informed consent:  
This study is a retrospective chart review. No informed consent is required.  
 
Ongoing respect for participants:  
Hard and electronic copies of data obtained in this study will be destroyed five years following 
completion of research. All data will have identifiers removed, and replaced with a study number, to 
protect confidentiality. Reports on the study will be statistically described and the anonymity of 
participants will be honoured.  
 
METHODOLOGICAL CHALLENGES AND STUDY LIMITATIONS:  
 
Majority of the patients attending this healthcare facility are of Black and Indian ethnicity. It 
therefore lends a challenge to generalising study findings across all racial backgrounds.  
 
Patients will be assessed from varying points from their rheumatoid arthritis onset, with varying 
effects of treatment. The clinical records at King Edward VIII Hospital are hard copies. Since a 
computerised filing system is not active, files including data from the initial clinical presentation, 
which may have been decades ago, including radiological and laboratory investigations, may be lost.  
 
The patients attending the clinic over many years, would have seen multiple clinicians, with an inter-
observer variance in characterisation of disease. This study utilises objective markers as defined by 
laboratory and radiological data, together with patient reporting of symptoms as categorised by the 
HAQ score, so as not to be skewed by subjective personal clinician interpretation.  
 
Certain aspects of this study rely on patient self-reporting, and there may be under- or over- 
reporting. 
 
This is a single study conducted in a single centre, which is urban and hospital based, with most of 
the patients attending this public healthcare service from low to middle income households.  
Conclusions from this study may not lend itself to generalisability across the population urban-rural 




Time lines and project management   
1. Literature search : June 2017 
2. Protocol preparation, drafting of questionnaire : July 2017  
3. Submission of protocol : August 2017 
4. Data collection and entry: September 2017 to November 2017  
5. Data analysis : December 2017  
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6. Final write up : January to February 2018  
 
Study team, contributors and authorship:  
The study team comprises the principal investigator, the supervisor, and a statistician. Contributions 
will be made by clinicians at the arthritis clinic and the medical outpatient clinics.  
Authorship credit is assigned to Dr P. Govender and Dr F. Paruk.  
All data will be collected and entered into an electronic format by the principal investigator.  
Statistical analysis will be performed by the statistician, Dr Wilbert Sibanda. 
Collating of clinically significant findings and data interpretation will be done by the principal 
investigator.  
There is no conflict of interest.  
 
Study funding : 
This study will incur no direct costs to the health facility.  
 
Publication of findings  
A scientific report will be submitted to the Department of Internal Medicine, Nelson R. Mandela 
School of Medicine, University of Kwa-Zulu Natal and the hospital. The results of the study will be 
submitted for presentation to scientific meetings and publication to local and/or international 
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South African Medical Journal guidelines for article submission 
Research 
Guideline word limit: 4 000 words 
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that clearly 
lay out the rationale for conducting the study. Some common reasons for conducting a study 
are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need 
to. Results should describe the study sample as well as the findings from the study itself, but 
all interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The 
conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. 
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text. 
Structured abstract 
 This should be 250-400 words, with the following recommended headings:  
o Background: why the study is being done and how it relates to other 
published work. 
o Objectives: what the study intends to establish 
o Methods: must include study design, number of participants, description of 
the intervention, primary and secondary outcomes, any specific analyses that 
were done on the data. 
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o Results: first sentence must be brief population and sample description; 
outline the results according to the methods described. Primary outcomes must 
be described first, even if they are not the most significant findings of the 
study. 
o Conclusion: must be supported by the data, include recommendations for 
further study/actions. 
 Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
 Do not include any references in the abstracts. 
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
 Objectives (within Introduction/Background): a clear statement of the main aim of the 
study and the major hypothesis tested or research question posed 
 Design (within Methods): including factors such as prospective, randomisation, 
blinding, placebo control, case control, crossover, criterion standards for diagnostic 
tests, etc. 
 Setting (within Methods): level of care, e.g. primary, secondary, number of 
participating centres. 
 Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural 
factors (e.g. smoking status, socioeconomic group, educational attainment, co-existing 
disease indicators, etc) that may have an impact on the study results. Clearly define 
how participants were enrolled, and describe selection and exclusion criteria. 
 Interventions (within Methods): what, how, when and for how long? Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
 Main outcome measures (within Methods): those as planned in the protocol, and those 





 Start with description of the population and sample. Include key characteristics of 
comparison groups. 
 Main results with (for quantitative studies) 95% confidence intervals and, where 
appropriate, the exact level of statistical significance and the number need to 
treat/harm. Whenever possible, state absolute rather than relative risks. 
 Do not replicate data in tables and in text. 
 If presenting mean and standard deviations, specify this clearly. Our house style is to 
present this as follows: 
 g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for 
mean (SD). 
 Leave interpretation to the Discussion section. The Results section should just report 
the findings as per the Methods section. 
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
 Statement of principal findings 
 Strengths and weaknesses of the study 
 Contribution to the body of knowledge 
 Strengths and weaknesses in relation to other studies 
 The meaning of the study – e.g. what this study means to clinicians and policymakers 
 Unanswered questions and recommendations for future research 
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 
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Study number   Date  
Age  Hospital file number   
Sex        M                       F Place of residence Peri-urban Rural 
Ethnicity        B                         I Occupation  
Level of education  None  Primary school High school University/College 
 
RHEUMATOID ARTHRITIS DISEASE PROFILE : 
Date of diagnosis   
Early morning stiffness duration in minutes 
Serology 
Rheumatoid factor Positive        negative 
Anti citrullinated peptide antibody  Positive        negative 
C reactive protein Initial :                            Current : 
Erythrocyte sedimentation rate  Initial :  Current :  
Xrays  HAQ score   
Normal  Tender joint count   
Juxta-articular osteopaenia Y/N Swollen joint count   
Joint space loss Y/N PGA  
Subchondral erosions Y/N MDGA  
Joint destruction Y/N SDAI  
Extra articular features of rheumatoid arthritis 
Subcutaneous nodules Y/N Vasculitis Y/N 
Scleritis/Episcleritis Y/N Osteoporosis  Y/N 
Sjogren’s syndrome  Y/N  
Pleural effusions Y/N Cardiomyopathy Y/N 
Interstitial lung disease Y/N Pericarditis Y/N 
Idiopathic pulmonary fibrosis Y/N Valvular heart disease Y/N 
Pulmonary nodules Y/N Coronary artery disease Y/N 
Pulmonary hypertension Y/N Atherosclerosis Y/N 
Anaemia Y/N Mononeuritis multiplex Y/N 
Thrombocytopaenia Y/N Peripheral neuropathy Y/N 
Leucopaenia Y/N Nerve entrapment Y/N 
 
Drug therapy :                                   Dose Duration 
Methotrexate    
Chloroquine   
Sulphasalazine   




Other  specify   
 
CARDIOVASCULAR DISEASE : 
Presence of cardiovascular disease  




Drug therapy  
Intervention  
 
Blood pressure  Smoker   Yes/ No 
Weight  Pack years   
Height  Weekly exercise habits  
Body mass index 25-29 kg/m2 30-34 kg/m2 35-39 kg/m2 >40 kg/m2 
If female, menoapausal Yes/No  
 
ECG findings   
Echocardiogram findings  Ejection fraction : 
 PAS : 
 Abnormality noted :  
 
CO-MORBIDITY AND FAMILY HISTORY : 
Co-morbidities Family history 
Diabetes Mellitus  Rheumatoid arthritis  
Hypertension  Cardiovascular disease  
Dyslipidaemia  Diabetes Mellitus  
Cerebrovascular accident   Hypertension  
Other   Dyslipidaemia  
HIV status  Cerebrovascular accident  
 
LABORATORY INVESTIGATIONS : 
Thyroid function test  Lipogram  
TSH  TC  Triglycerides  
T4  HDL   LDL  
T3  Full blood count  
HbA1C  Hb   
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Appendix 4: Data Collection Tool 
Simplified Disease Activity Index 
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